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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a terminal cancer projected to become the
leading cause of cancer-related deaths in North American by the year 2030. Constitutive
activation of KRAS is seen in >90% of PDAC cases. In addition to oncogenic KRAS
activity, pancreatic injury is key contributor to PDAC initiation and progression.
Activating transcription factor 3 (ATF3) is required for the formation of preneoplastic
lesions in acute pancreatitis. However, unlike recurrent or chronic forms of pancreatitis,
acute pancreatitis is not predictive of PDAC. Therefore, the goal of this thesis is to
determine the role of ATF3 in recurrent pancreatitis and PDAC. I hypothesize that ATF3
is required for persistent acinar-to-ductal cell metaplasia (ADM) and pancreatic
intraepithelial neoplasia (PanIN) in recurrent pancreatitis and PDAC. To address this
hypothesis, I used mice carrying a targeted deletion of the Atf3 translation start site
(Atf3-/-) and exposed them to an experimental model of recurrent pancreatic injury or bred
them with mice allowing inducible activation of oncogenic KRAS (KRASLSL-G12D/+)
specifically in pancreatic acinar cells. The absence of ATF3 reduced ADM and improved
pancreatic tissue regeneration in response to recurrent pancreatitis. In addition, KRASG12D mice lacking Atf3 showed reduced high grade PanIN lesions compared to mice
expressing KRAS-G12D and ATF3. These results suggest an important role for ATF3 in
PDAC initiation and progression from recurrent forms of pancreatitis.

Keywords
Pancreatic ductal adenocarcinoma, pancreatitis, acinar-to-ductal cell metaplasia,
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Summary for Lay Audience
This thesis examines the role of a protein called Activating Transcription Factor 3
(ATF3) in experimental models of pancreatitis and pancreatic cancer in mice. Pancreatitis
is the inflammation of the pancreas as a result of injury, which increases the susceptibility
of developing pancreatic cancer. Previous work done in our laboratory looked at acute
forms of pancreatitis and showed that the germline loss of Atf3 expression was beneficial
for pancreatic tissue regeneration. Next, I wanted to know if the loss of ATF3 was also
beneficial in the context of recurrent forms of pancreatitis (greater susceptibility for
pancreatic cancer in comparison to acute forms) and pancreatic cancer. My work showed
that mice lacking ATF3 expression in recurrent forms of pancreatitis had better tissue
regeneration and lower number of lesions, which have the potential of developing into
cancer. In my pancreatic cancer model, the loss of ATF3 reduced the number of highly
developed lesions. My results indicate that there may be a potential in therapeutically
targeting ATF3 in pancreatic cancer for better outcome.
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CHAPTER 1

1

INTRODUCTION

1.1 Overview
This thesis provides important insights for the transition from recurrent pancreatitis (RP)
to pancreatic ductal adenocarcinoma (PDAC). Activating Transcription Factor 3 (AFT3),
mediator of the unfolded protein response pathway (UPR), has been associated with
multiple cancer types and previous work from our laboratory suggests it is required for
the de-differentiation of acinar cells in the context of acute pancreatic injury (Thompson
et al., 2009; Yin et al., 2010; Wu et al., 2010; Fazio et al., 2017). However, ATF3 to our
knowledge has not been studied in murine models of chronic or recurrent pancreatitis, nor
in PDAC to date. While a wide range of intrinsic and extrinsic signalling pathways have
been studied in PDAC, there is still a gap in understanding the molecular events that
promote KRAS-mediated initiation and progression of PDAC (Bryant et al., 2014;
O’Hagan & Heyer, 2011; Liu & Kaufman, 2003; Ron & Walter, 2007). Therefore,
examining additional signalling factors, such as ATF3 will help us understand how the
cellular response to recurrent forms of injury promote progression to PDAC. Previous
work in our laboratory showed ATF3 is a mediator of preneoplastic lesions in acute
pancreatitis (Fazio et al., 2017). This thesis investigates ATF3’s role in recurrent
pancreatic injury and in the context of oncogenic KRAS-(G12D). Molecular markers of
preneoplastic lesions were examined during injury, recovery and in advanced PanIN
lesions in the absence of ATF3.
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1.2 PDAC
PDAC constitutes 95% of pancreatic cancers and has a very poor overall 5-year survival
rate of only 8%. PDAC is projected to be the leading cause of cancer-related deaths in
North America by the year 2030 (Conroy et al., 2011; Koikawa et al., 2018). A large
majority of PDAC patients are diagnosed at the late stages of the disease, when
metastasis has already taken place (Zhang et al., 2019). The lack of early clinical
symptoms before PDAC develops and metastasizes makes early detection difficult
(Zhang et al., 2019). Surgical resection is considered the most effective treatment,
although 80% of these patients are noted to relapse soon after surgery (Low et al., 2011).
Cancerous tissue that is surgically resected is commonly noted as a solid mass upon gross
morphologically examination. This is reflective of the tumour microenvironment being
highly fibrotic in addition to showing high levels of immune cell infiltration (Kleeff and
Jorg, 2016; Sener et al., 1999). Due to the highly heterogenous and stromal nature of the
disease, effective drug delivery remains a problem when treating PDAC (Jacobetz et al.,
2013). Patients with late stage PDAC without the option of resection are treated with
either gemcitabine (median survival 6.8 months) or FOLFIRINOX (median survival 11.1
months) chemotherapeutics (Ahn et al., 2017; Von Hoff et al., 2013; Conroy et al., 2011).
Combining both gemcitabine and FORFIRINOX shows no beneficial outcome compared
to either drug alone (Conroy et al., 2011). Based on these findings, there is a dire need for
better biomarkers that are able to detect and diagnose the disease at earlier stages.
The origin of PDAC as demonstrated by animal and human studies show emergence from
late stage neoplastic lesions called pancreatic intraepithelial neoplasms (PanINs) (Hruban
et al., 2000). Histologically, PanIN development and progression occurs in stages. Early
PanINs (PanIN1A/B and PanIN2) are classified by the replacement of cuboidal duct
structures with columnar mucinous epithelium with low levels of dysplasia. Focal
PanIN1A/B lesions are known to be observed in non-diseased pancreatic tissue (Di
Magliano & Logsdon, 2013). Intermediate (PanIN2) and high-grade PanINs (PanIN3) are
characterized by varying degrees of nuclear irregularity (nuclear atypia), loss of cell
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polarity, luminal necrosis and increased levels of dysplasia (Makohon-Moore et al., 2016;
Hruban et al., 2008; Basturk et al., 2015).
The cell of origin of precursor lesions is debated (Ferreira et al., 2017; Bailey et al., 2014;
Rooman & Real, 2012). It has been demonstrated that PDAC can arise from ductal cells
which form the conduit system that carries secreted enzymes from pancreatic acinar cells
to the duodenum (Ferreira et al., 2017; Lee et al., 2018) or from pancreatic acinar cells
(Chen et al., 2018; Bailey et al., 2014; Rooman & Real, 2012). Pancreatic acinar cells are
highly polarized, enzyme secreting cells within the exocrine pancreas, which makes up
the majority of the pancreas (>90%) (Tsunoda et al., 1996). Upon neuronal or hormonal
stimulation (Tsunoda et al., 1996; Ogami & Otsuki, 1998) acinar cells release synthesized
and stored pro-enzymes by regulated exocytosis into the ductal network (Reichert and
Rustgi, 2011). In addition to lesion formation from acinar cells, the cells of the stromal
microenvironment during injury also play a role in further progressing PanIN lesions by
cell-to-cell crosstalk.

1.2.1 PDAC microenvironment
The microenvironment in PDAC plays a major role in progression and metastasis of
PDAC (Macherla et al., 2018; Ogier et al., 2018). Standard therapies including immunebased therapies are difficult to develop due to the encapsulation of PDAC cells in the
tumour-associated fibroinflammatory network (Zhang et al., 2019). The highly stromal
nature of PDAC prevents drug delivery and the mobilization of anti-tumour cells from
destroying cancer cells (Olive et al., 2009; Neesse et al., 2011; Hingorani & Tuveson,
2003). Fibroblast cells normally reside between pancreatic cells and help model the
extracellular matrix (ECM; Bailey et al., 2008). Early PanIN lesions secrete the sonic
hedgehog signalling (shh) molecule and activate fibroblast cells into cancer-associated
fibroblast cells (CAFs; Yauch et al., 2008; Bailey et al., 2008). The deregulation of the
ECM by CAFs results in significantly more deposits of collagen protein leading to
fibrosis (Zhang et al., 2019). CAFs make up a large proportion of the dysplastic
constituents of the stroma and are one of the known hallmarks of PDAC (Collins et al.,
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2012). CAFs are known to have different potential roles in PDAC; studies have
demonstrated both a pro-tumorigenic role (Yauch et al., 2008) or a tumour suppressor
role (Kalluri & Zeisberg, 2006).
In addition to fibroblast activation and extensive fibrosis, immune cell signalling has a
major role in PDAC (Gardian et al., 2012; Kurahara et al., 2011; Helm et al., 2014).
Immune cells that are highly prevalent in PDAC and are derived from hematopoietic
stem cells of the bone marrow (Nowarski et al., 2013). In particular, myeloid cells
derived from hematopoietic stem cells can be subcategorized into granulocytes, mast
cells, monocytes, dendritic cells, macrophages and play a vital role in fighting infection
and help heal wounds (Nowarski et al., 2013). One of the best characterized subsets of
these cells in PDAC are tumour associated macrophages (TAMs). TAMs can either be
derived from circulating monocytes or activated locally by cytokine signalling on
resident macrophages (Clark et al., 2007). In PDAC, cytokines secreted by neoplastic
ductal lesions include monocyte chemoattractant protein-1 (MCP-1), more currently
known as C-C Motif Chemokine Ligand 2 (CCL2) (Rambaldi et al., 1987; Murdoch et
al., 2004). In addition to local activation of macrophages to TAMs, increased serum
levels of CCL2 correlate with increased TAM attraction and infiltration of neoplastic
lesions from the blood stream (Monti et al., 2003). TAMs have been implicated in the
initiation and expansion of tumour cells (Mitchem et al., 2013) along with promoting
epithelial to mesenchymal transition (EMT) (Helm et al., 2014) and PDAC metastasis
(Gardian et al., 2012; Kurahara et al., 2011).

1.2.2 Genetic mutations linked to PDAC
A number of studies assessing genetic risk factors for PDAC show an estimated 10% of
patients have an inherited susceptibility for PDAC (Lynch, et al., 2010; Hruban et al.,
1998; Schenk et al., 2001). Case-control and cohort studies demonstrate individuals with
a family history of PDAC have a 1.9- to 13-fold risk factor for PDAC when compared to
individuals with no family history (Ghadirian et al., 1991; Jacobs et al., 2010; Klein,
2012). In addition, the odds of PDAC increase with increasing number of first-degree
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relatives with the disease. The odds ratio for PDAC is 1.76-fold higher for an individual
with one first-degree relative with PDAC and 4.26-fold higher with two first-degree
relatives (Jacobs et al., 2010). Individuals that have greater odds of PDAC development
are typically carriers of multiple genetic mutations that have been linked to the disease
(Reznik et al., 2014; Pogue-Geile et al., 2006).
Specific inherited mutations for breast cancer type 2 susceptibility protein (BRCA2), p16
and PALLADIN increase the risk for PDAC development (Reznik et al., 2014). The
BRCA2 gene is involved in the Fanconi anemia pathway and is responsible for double
stranded DNA break repair and synthesis phase DNA damage checkpoint control (van
der Heijden et al., 2005; B. Xia et al., 2006). Inherited mutations in BRCA2 result in
impaired cytokinesis, proliferation arrest and genomic instability (Sharan et al., 1997;
Patel et al., 1998; Couch et al., 2007). Individuals with this mutation have a 3.5- to 10fold risk factor for PDAC development compared to non-carriers (Breast Cancer Linkage
Consortium, 1999; van Asperen et al., 2005). In addition, PALLD overexpression has
been linked to PDAC development (Pogue-Geile et al., 2006). PALLADIN is responsible
for encoding components of the cytoskeleton that help with cellular motility. Cells with
PALLD overexpression show increased cellular motility (Pogue-Geile et al., 2006).
Furthermore, germline mutations in the tumour suppressor gene CDKN2A, encoding
both p16INK4A and p19ARF, increases the risk for PDAC. The p16INK4A protein is
responsible for the regulation of cell cycle through the G1 to S phase transition
(Schneider & Schmid, 2003). The mutated p16INK4A protein has been reported to act
jointly with oncogenic kirsten rat sarcoma viral oncogene homolog (KRAS) and
accelerate tumour progression (Hezel, et al., 2006).
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1.2.3 Oncogenic KRAS and downstream effectors
The most common mutation in early neoplastic lesions (PanIN1) occur in the KRAS gene.
More than 90% of PDAC patients carry an activating mutation in KRAS, with a G12D
conversion observed 98% of the time (Bryant et al., 2014; O’Hagan & Heyer, 2011;
James et al., 2018; Eser et al., 2014). The G12D mutation causes constitutive activation
of KRAS by preventing GTP hydrolysis (Bos, 1989; O’Hagan & Heyer, 2011).
Physiologically, the human RAS protein is a small (21 kDa) plasma membrane bound
GTPase protein, responsible for proliferation, differentiation and cell migration by
linking multiple downstream signalling pathways. KRAS activation promotes mitogen
activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) signalling
(Bryant et al., 2014). In the pancreas, KRAS cycles between a GTP-bound “ON switch”
and GDP-bound “OFF switch” (Bryant et al., 2014; Di Magliano & Logsdon, 2013). The
proteins responsible for affecting the molecular switch in KRAS include guanine
nucleotide exchange factors (RasGEFs) and GTPase-activating proteins (RasGAPs)
(Bryant et al., 2014) respectively. RasGEFs activate KRAS by replacing GDP with GTP,
while RasGAPs hydrolyze GTP to GDP and inactivate KRAS activity (Bryant et al.,
2014). Genetic mouse models that utilize the cre/loxP system, which allow for temporal
oncogenic KRAS activation, demonstrate constitutively active KRAS is needed for
progression, and maintenance of preneoplastic lesions as well as promote metastasis
(Ying et al., 2012; Collins et al., 2012). The development of therapy targeting
constitutively active KRAS has been unsuccessful to date due to the lack of direct, potent
and selective inhibitors (Nussinov et al., 2018) along with random spontaneous KRAS
mutations with age (Di Magliano & Logsdon). Further, Singh et al., (2009) showed a
subset of PDAC cells associated with epithelial to mesenchymal transition (EMT) that
did not respond to KRAS inactivation. Despite these findings, there have been increasing
efforts made in developing potential inhibitors to target KRAS-(G12D) (Holderfield,
2018; Lu, et al., 2016; Zeng et al., 2017).
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Figure 1.1. Progression from normal to diseased pancreas with the temporal
association of known genetic mutations. The Kras gene is initially mutated resulting in
constitutive activation of KRAS in acinar cells leading to ductal programing. Lower
grade PanIN1A/B lesions form in the presence of oncogenic KRAS and are characterized
by columnar mucinous epithelium. The second most common mutation is in the p16
protein which further progresses PanIN1 lesions to PanIN2 in the presence of oncogenic
KRAS characterized by nuclear atypia and a lower degree of surrounding desmoplasia.
Further mutations in TP53, SMAD4 and BRCA2 result in high grade PanIN3 lesions and
PDAC, which is characterized by high levels of nuclear atypia, epithelial folding and
higher levels of surrounding desmoplasia (Figure adapted from Morris et al., 2010).
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Currently the inability to directly target oncogenic KRAS has led to targeting potential
downstream effectors of KRAS. The two major downstream pathways include RAFMEK-ERK (MAPK) and PI3K-AKT signalling (Lim et al., 2005; Feldmann et al., 2010;
Collisson et al., 2012; Eser et al., 2013). The MAPK pathway involves a series of
downstream phosphorylation events where RAF (MAPKKK) is activated by GTP bound
KRAS. Subsequently, RAF phosphorylates MEK (MAPKK) and further MEK
phosphorylates ERK (MAPK). Phosphorylated ERK translocates to the nucleus and
phosphorylates transcription factors, which induce gene expression (Crespo & León,
2000; Schubbert et al., 2007). Oncogenic RAF alone is sufficient to induce PanIN lesion
formation in the absence of constitutively active KRAS (Collins et al., 2012b). The
presence of oncogenic KRAS along with constitutively active RAF shows more severe
high-grade PanIN formation compared to oncogenic KRAS alone (Collisson et al., 2012).
This highlights that downstream mediators are capable of inducing lesion formation even
in the absence of oncogenic KRAS.
The second major intrinsic pathway involved in cell survival is PI3K-AKT signalling.
Phosphatidyl inositol 3 kinase (PI3K) is phosphorylated by receptor tyrosine kinases
(RTKs) and further phosphorylates downstream PIP2 producing phosphatidylinositol
(3,4,5)-trisphosphate (PIP3) (Castellano & Downward, 2011). PIP3 subsequently binds
and activates AKT/PKB leading to a cascade of phosphorylation events downstream
(Castellano & Downward, 2011; Eser et al., 2013). Blocking both RAF-MEK-ERK and
PI3K-AKT results in a delayed induction of lung tumours compared to non-inhibitor
controls (Castellano & Downward, 2011). In contrast, mutations in the EGFR signalling
pathway and focal low grade PanIN lesions do occur spontaneously and are present in
normal pancreatic tissue. Therefore, it is believed that additional genetic or
environmental factors are necessary to initiate full blown carcinogenesis in addition to
constitutively active KRAS (Di Magliano & Logsdon, 2013).
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Figure 1.2. EGFR signalling pathway. The EGFR pathway is split into two main
intracellular signalling streams (MAPK and PI3K) involved in cell survival and
proliferation. The intracellular MAPK signalling stream is activated by a cascade of
phosphorylation events that results in the translocation of phosphorylated ERK1/2 to the
nucleus where it phosphorylates transcription factors. In the second signalling stream,
PI3K is phosphorylated by RTKs where it subsequently phosphorylates PIP2 to PIP3 and
as a result AKT is activated downstream.
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1.2.4 Additional Genetic Mutations
Additional mutational burden helps progress low grade neoplastic ductal lesions with
oncogenic KRAS into PDAC (Bryant et al., 2014; O’Hagan & Heyer, 2011; James et al.,
2018). Progression through the PanIN stages to PDAC includes additional mutations in
TP53, SMAD4 and other key genes. In 50-75% of PDAC cases the TP53 gene is mutated
(Morton et al., 2010; The Cancer Genome Atlas Research Network, 2017). Mutations in
TP53 specifically drive KRAS-induced neoplastic lesions to PDAC (Morton et al., 2010)
and is thought to further induce metastasis (Weissmueller et al., 2014). Further mutations
in SMAD4 (30-64% of PDAC show SMAD4 mutations) have been implicated in
progression of low grade PanIN lesions to PDAC as demonstrated by genomic
sequencing and immunohistochemistry techniques (Waddell et al., 2015; Ormanns et al.,
2017). Physiologically, SMAD4 is a transcription factor involved in the transforming
growth factor beta (TGF-β) pathway, which induces genes expression based on
microenvironmental factors (Waddell et al., 2015; Ormanns et al., 2017). Conversely,
genetics is not a major factor (90% PDAC cases have no additional mutated gene)
therefore, environmental factors most likely are involved for the progression of PDAC.

1.2.5 Environmental factors linked to PDAC
Environmental factors such as chronic alcohol consumption and smoking are linked to
PDAC development (Tramacere et al., 2010; Yadav & Whitcomb, 2010). Chronic
alcohol consumption remains to be a significant risk factor for PDAC (Schenker &
Montalvo, 1998; Tramacere et al., 2010). In addition, it is estimated that 25% of PDAC
cases are due to the high prevalence of smoking worldwide (Maisonneuve & Lowenfels,
2010; Vrieling et al., 2010). This is complicated by individuals who abuse both alcohol
and smoke concurrently (Yadav & Whitcomb, 2010).
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Other factors that are linked to the development of PDAC include obesity and type 2
diabetes mellitus (T2DM). Obese individuals (BMI > 40 kg/m2) have a 3-fold higher risk
factor for PDAC both in men and women compared non-obese controls (Calle et al.,
2003). Secondly, individuals with high insulin resistance have an estimated 3-fold
increase for the risk of developing PDAC (Stolzenberg-Solomon et al., 2005). These
studies suggest a strong correlation between stressors of the pancreas and PDAC.
However, the strongest risk factor for PDAC is pancreatitis, in particular, recurrent and
chronic forms of pancreatitis (Yadav & Lowenfels, 2006; Fagenholz et al., 2007; Krishna
et al., 2017; Lew et al., 2017).

1.3 Pancreatitis
Pancreatitis is a severe disease marked by parenchymal and systemic inflammation,
fibrosis, and necrosis (Lew et al., 2017). Pancreatitis can be classified into three main
categories: acute, recurrent, and chronic (Yadav & Lowenfels, 2013). Acute pancreatitis
is defined by the rapid onset inflammation of the pancreas and is known to be reversible
(Crockett et al. 2018). If acute pancreatic injury occurs more than twice it is defined as
recurrent pancreatitis (RP) (Lankisch et al., 2009; Nøjgaard et al., 2011). The incidence
of RP worldwide is 8-10/100,000 and can substantially increase the likelihood of
developing irreversible chronic pancreatitis (CP) (Machicado & Yadav, 2017). CP occurs
as a result of repeated insult from RP producing inflammation and fibrosis of the exocrine
pancreas leading to lasting changes of pancreatic architecture (Machicado & Yadav,
2017). The literature strongly correlates RP to the development of CP (Yadav &
Lowenfels, 2006; Fagenholz et al., 2007; Krishna et al., 2017; Lew et al., 2017). Chronic
pancreatitis is a significant risk factor for PDAC development (Guda et al., 2018; Yadav
& Lowenfels, 2013).
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1.3.1 Genetic and environmental factors linked to pancreatitis
Genetic factors linked to the development of pancreatitis are well known (Schneider et
al., 2004; Rosendahl et al., 2008; Mayerle et al., 2018). The first gene mutation identified
as being correlated to pancreatitis was in the serine protease 1 (PRSS1) gene which
encodes cationic trypsinogen (Whitcomb et al., 1996). In physiological conditions,
trypsinogen is maintained within acinar cells in an inactive state and only becomes active
when released into the duodenum and enzymatically cleaved (Whitcomb et al., 1996;
Mayerle et al., 2018). Gain of function mutations in PRSS1 lead to premature activation
of trypsinogen within acinar cells that is resistant to inhibition and causes autodigestion
of the cell leading to pancreatitis. Mutations in the PRSS1 gene are inherited in an
autosomal dominant manner but do not show complete penetrance (Whitcomb et al.,
1996; Charnley, 2003). Additional mutations that can lead to pancreatitis occur within
serine protease inhibitor Kazal-type 1 (SPINK1) and chymotrypsin C (CTRC) genes
(Schneider et al., 2004; Rosendahl et al., 2008). Both SPINK1 and CTRC regulate trypsin
by encoding proteins that inhibit its premature activation. Loss of function mutations in
either SPINK1 and CTRC can lead to the premature activation of trypsinogen to trypsin
(Schneider et al., 2004; Rosendahl et al., 2008). In addition, intracellular activation of
proteases, like trypsin, can result in the activation of nuclear factor kappa-light-chainenhancer of activated B cells (NF-κB): a master regulator of the inflammatory pathway,
which can further propagate the disease (Jakkampudi et al., 2016). However, NF-κB can
be activated independent of premature protease activation and work independently of
proteases in acinar cells to initiate pancreatitis (Baumann et al., 2007).
Environmental factors also contribute to the formation of pancreatitis. Risk factors
include smoking, a Western diet and chronic alcohol consumption, which are correlated
with the development of pancreatitis (Maisonneuve & Lowenfels, 2010; Vrieling et al.,
2010; Tramacere et al., 2010). Additional factors, such as blockage of the common bile
duct, also pose a risk for the development of pancreatitis. Normally, digestive enzymes of
the pancreas flow through the common pancreatic duct into the duodenum. Blockage of
the common bile duct can restrict the flow of digestive enzymes into the duodenum
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causing a back flow of enzymes into parenchymal tissue leading to inflammation and
digestion of healthy cells (Malik, 2015). The blockage of the pancreatic common duct is
the most common cause of AP in the human adult population (35-75% of acute
pancreatitis cases; Trust et al., 2011). Further, anatomical abnormalities can lead to the
development of pancreatitis. For example, pancreas divisum (abnormal anatomy of
pancreatic ducts) can cause RP and subsequently result in CP (Lew et al., 2017). On the
other hand, it is important to note that 10-30% of patients with pancreatitis have no
attributable cause, which can later lead to idiopathic onset of CP in patients and increase
the risk for PDAC development (Lew et al., 2017).

1.4 Models used to study pancreatitis and PDAC
1.4.1 Environmental models of pancreatitis
To delineate the mechanisms that affect progression and severity of pancreatitis a wide
range of animal models have been utilized (Saluja et al., 1985; Zhan et al., 2016; Hegyi et
al., 2004). The introduction of L-arginine is one method of inducing pancreatitis (Hyun &
Lee, 2014; Cuthbertson & Christophi, 2006). A single injection (500 mg/100 g body
weight) induces severe acute necrotizing pancreatitis in rats (Hegyi et al., 2004; Tani et
al., 1990). This model emulates clinical features of sudden onset acute pancreatitis such
as multi-organ failure (Steinberg & Tenner, 1994; Renner et al., 1985; Karimgani et al.,
1992). However, L-arginine’s pathogenic mechanism of pancreatitis is unclear, although
proposed mechanisms do exist in the literature (Czakó et al., 1998; Takács et al., 2002;
Rakonczay et al., 2003). Secondly, to mimick pancreatitis caused by gallstone restriction
of the main pancreatic duct, experimentally blocking the main duct by means of ligation
can be used (Zhan et al., 2016; Kirkbride, 1912; Sendler et al., 2015; Xiao et al., 2017).
This model is highly technical, invasive and is rarely used for CP studies (Lerch &
Gorelick, 2013). Mainly, the pancreatic ductal ligation model is used in rodents to induce
and study acute pancreatitis which mimicks human biliary acute pancreatitis and at later
time points: chronic pancreatitis (Zhan et al., 2016). Despite the two models mentioned,
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cerulein-induced-pancreatitis (CIP) remains the most common method of studying
pancreatitis.
Cerulein is a cholecystokinin (CCK) hormone analog (Niederau et al., 1985) that can be
administered at supraphysiologic levels preventing zymogen granule exocytosis within
acinar cells. This results in pancreatitis as a result of acinar cell autolysis (Saluja et al.,
1985). Intracellular changes in calcium signalling and the activation of the inflammatory
pathway NF-kB are responsible for inducing pancreatitis as a result of CIP (Krüger et al.,
2000; Mooren et al., 2003). The activation of the inflammatory pathway and autolysis of
acinar cells produce chemokines and cytokines such as interleukin 6 (IL-6) and
chemoattractant proteins that signal inflammatory cells such as neutrophils and
macrophages to the surrounding tissue (Abdulla et al., 2011; Brady et al., 2002). The
inflammatory response in CIP is representative of what is seen in human pancreatitis
(Lew et al., 2017). In addition, the CIP model results in high levels of fibrosis
representative of what is seen in human patients (Lew et al., 2017). Further, CIP activates
resident fibroblast cells to active pancreatic stellate cells (PSC) (Yauch et al., 2008;
Bailey et al., 2008). Once activated, PSCs secrete ECM proteins (mainly collagen 1) that
results in extensive fibrosis. This is further exacerbated by macrophages that release
TNF-α and signal the activation of stellate cells (Sendler et al., 2013). To recapitulate RP,
multiple injections of cerulein can be given over the course of several weeks. This results
in persistent exocrine tissue damage, immune cell infiltration and fibrosis, consistent with
human patients that have CP (Neuschwander-Tetri et al., 2000). One caveat to this model
is that pancreatitis completely resolves after the cessation of cerulein administration in
mouse models (Lugea et al., 2006). This is unlike the self-sustained, irreversible CP seen
in human patients (Etemad & Whitcomb, 2001).

1.4.2 Genetic models of pancreatitis and PDAC
A number of transgenic mouse models have been generated to study pancreatitis. Since
pre-mature activation of trypsinogen is a key initiator of pancreatitis, transgenic mice
carrying the mutant variant of the PRSS1 gene have been generated (Archer et al., 2006;
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Selig et al., 2006; Athwal et al., 2014). Mice carrying the mutant human PRSS1 transgene
fail to develop pancreatitis spontaneously (Archer et al., 2006). This is likely due to low
penetrance of the transgene (Archer et al., 2006; Archer et al, 2014). However, a more
severe pancreatitis phenotype occurs upon cerulein injection in mice carrying the mutant
PRSS1 gene compared to wild-type mice treated with ceruelin (Archer et al., 2006;
Athwal et al., 2014). Secondly, the IKKα complex, which is a regulator of NF-κB, can
also be specifically targeted to induce pancreatitis (Li et al., 2013). Loss of IKKα causes
spontaneous pancreatic injury, along with acinar cell atrophy, fibrosis and the presence of
tubular structures in the pancreas of mice (Li et al., 2013).
The number of different transgenic mouse models developed for studying PDAC is
significant (Hingorani et al. 2003; Guerra et al., 2007; Guerra et al., 2011; Westphalen &
Olive, 2012). The vast majority of the genetic mouse models express the mutant
KRASG12D by pancreas-specific cre-recombination (Guerra et al., 2007; Guerra et al.,
2011; Krah et al., 2015). In non-inducible models, KRASG12D is expressed early in
embryonic development (E8.5) using promoters specific to the pancreas such as
pancreatic and duodenal homeobox 1 (Pdx1) and pancreas associated transcription factor
1a (PTF1a) (Hingorani et al., 2003). These mice develop PanIN lesions that progress to
metastatic PDAC within 1-year of KRASG12D activation (Hingorani et al., 2003). Often,
the transgenic models also incorporate mutations in tumour suppressor genes such as
TP53, SMAD4 and CDKN2A (Guerra et al., 2007; Guerra et al., 2011; Pérez–Mancera et
al 2012; Westphalen & Olive, 2012). Mice carrying TP53 mutations along with mutant
KRASG12D (lox-stop-lox [LSL] KRASG12D/+; LSL- Trp53R172H/+; Pdx-1Cre; KPC) do not
show any signs of pancreatitis or neoplastic lesions at birth (Guerra et al., 2011).
However, KPC mice develop PanIN lesions and show fibrosis by 8-10 weeks of age
(Guerra et al., 2007; Guerra et al., 2011). Interestingly, the KPC model has an immunomicroenvironment that mirrors the one seen in human patients (Bayne et al., 2012; Beatty
et al., 2011). In addition, PDAC clinical features are present in KPC mouse models:
ascites, biliary obstruction and cachexia (Feig et al., 2013; Jacobetz et al., 2013). One
caveat to this mouse model is that KRAS and TP53 mutations occur as soon as the driver
gene is activated embryonically, which does not resemble the developmental timeline of
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PDAC seen in older human adults (Guerra et al., 2007; Guerra et al., 2011; Pérez–
Mancera et al 2012; Westphalen & Olive, 2012). Therefore, I have chosen to use a mouse
model that utilizes the loxP/creERT system to induce KRASG12D expression temporally in
adult acinar cells (Krah et al., 2015). The activation of KRASG12D in adult acinar cells
alone is generally not sufficient to induce PDAC on its own. Additional environmental
stress like cerulein based pancreatitis is needed for PDAC development (Krah et al.,
2015). In this thesis the loxP/creERT system was utilized to induce KRASG12D expression
in the adult pancreas and cerulein was further administered to induce PDAC
development.

1.5 Acinar-ductal-cell metaplasia
To define the origin of precursor PanIN lesions, reporter genes can be included in the
transgenic mouse models. Multiple reporter systems exist (Vacaru et al., 2014; Chen et
al., 2018; de Latouliere et al., 2016) including Gfp, Yfp, mCherry, that are targeted to the
Rosa26R allele (Krah et al., 2015). Lineage tracing experiments show acinar cells
undergo trans-differentiation or de-differentiation to ductal-like complexes by a process
called acinar-to-duct cell metaplasia (ADM) (Stanger & Hebrok, 2013; Pinho et al., 2011;
Rooman & Real, 2012). This process is believed to be essential for the regeneration of
parenchymal tissue from progenitor-like cells to cope for the loss of tissue mass
associated with injury (Liou et al., 2013; Houbracken et al. 2011). However, when
pancreatic injury is persistent or when genetic mutations are acquired, ADM is prevented
from re-differentiation back to acinar cells and can further progress to form PanIN lesions
increasing the risk of PDAC development (Kopp et al., 2012). There is evidence that
ADM occurs in both mouse models (Sandgren et al., 1990) and in humans (Liu et al.,
2016). In both mice and humans, transcription factors and signaling pathways are known
to regulate the formation of ADM (Ardito et al., 2012; Guerra et al., 2007; Wagner et al.,
1998; Campos et al., 2013). Therefore, it is critical to study and understand molecular
factors involved in ADM development and progression.
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1.5.1 Transcription factors involved in ADM
Transcription factors involved in maintaining acinar cell identity are down-regulated in
cells undergoing ADM (Rodolosse et al., 2004). In addition, transcription factors
involved in the maintenance of ductal cell identity are up-regulated (Park et al., 2011;
Miyatsuka, 2006; Shi et al., 2013; Liou et al., 2013). Two key basic helix-loop-helix
transcription factors, pancreas transcription factor 1 complex (Ptf1) and Mist1 are vital in
maintaining acinar cell identity (Krapp et al., 1998; Rodolosse et al., 2004; Pin et al.,
2001). Along with maintaining acinar cell identity, PTF1 regulates the production of
digestive enzymes such as amylase and carboxypeptidase 1 in acinar cells (Krapp et al.,
1998; Rodolosse et al., 2004). The PTF1 protein exists in a complex with recombining
protein suppressor of hairless (RBPJ) and PTF1A (Masui et al., 2010). Mechanistically,
the PTF1 complex signals p300/CREB to acetylate the PTF1A subunit which induces its
transcriptional activity (Campos et al., 2013). The complete loss of Ptf1a in the adult
pancreas promotes metastatic PDAC development as a result of ADM progression (Krah
et al., 2015). A second key regulator of acinar cell identity is Mist1, which is required for
complete acinar cell maturation, establishment of cellular polarity, gap junction
communication and appropriate regulation of exocytosis (Pin et al., 2001). Inflammation
as a result of pancreatitis results in the downregulation of Mist1 (Kowalik et al., 2007;
Karki et al., 2015). Forced expression of Mist1 rescues the pancreatitis phenotype and
prevents ADM development. In contrast, complete ablation of Mist1 results in incomplete
acinar cell maturation increasing susceptibility to pancreatic injury (Rukstalis et al., 2003;
Karki et al., 2015).
Conversely, the main transcription factors that are upregulated in the ADM program are
the Sry-related high-mobility group box 9 (Sox9) and pancreatic and duodenal homeobox
1 (Pdx1) (Park et al., 2011; Miyatsuka, 2006; Shi et al., 2013; Liou et al., 2013).
Physiologically, SOX9 protein expression is minimal in acinar cells but is expressed in
some duct cells and centroacinar cells (Kopp et al., 2011; Furuyama et al., 2011).
Expression of SOX9 is up-regulated in acinar cells as a response to inflammation or other
forms of pancreatic injury. High levels of SOX9 expression up-regulate expression of

18
genes such as cytokeratin 19 (Ck19), which is a marker of duct cells (Prévot et al., 2012;
Carrière et al., 2011). In patient PDAC samples, SOX9 is expressed in PanIN lesions and
tumour cells (Shroff et al., 2014). In addition, resected human PDAC samples show a
correlation between SOX9 expression and increased EGFR signalling (Grimont et al.,
2015). In mice, the absence of SOX9 results in lower EGFR signalling and reduces
precursor lesion progression (Grimont et al., 2015). Secondly, PDX1 is vital for
pancreatic development and is expressed in progenitor cells as well as β cells of the
endocrine pancreas, but it is not normally expressed in adult acinar cells. (Wescott et al.,
2009; Marty-Santos & Cleaver, 2016; Hale et al., 2005; Gu et al., 2002). Like Sox9, Pdx1
is up-regulated in acinar cells during pancreatic injury and has an oncogenic role upon
neoplastic transformation (Roy et al., 2016; Park et al., 2011; Miyatsuka, 2006).
Constitutively active Pdx1 expression in mice leads to spontaneous formation of duct-like
structures (Miyatsuka, 2006).

1.5.2 Signalling pathways involved in ADM
Signalling pathways promoting ADM have been extensively studied in animal and cell
culture models (Sandgren et al., 1990; Liou et al., 2015; Morris et al., 2010). Early work
done on acinar cell culture models focused on the EGFR signaling pathway and
demonstrated a correlation between EGFR signalling and ADM formation (Sandgren et
al., 1990). Similarly, activating SMAD4 in human pancreatic cultures with transforming
growth factor beta (TGF-β) have been correlated to the development of ADM (Liu et al.,
2016). Secondly, in animal models, early cross-talk between inflammatory cells and
KRAS activation has been linked to irreversible ADM development (Liou et al., 2016).
Other known signalling pathways involved in ADM include NOTCH, Wnt and Hedgehog
(Siveke et al., 2008; Fendrich et al., 2008; Morris et al., 2010). To better understand the
interaction between intracellular and extracellular signalling pathways, additional
pathways that promote ADM need to be studied. The unfolded protein response pathway
(UPR) is one potential pathway that may help better understand ADM formation.
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Figure 1.3. Acinar-to-Ductal cell Metaplasia (ADM). Pancreatic injury results in acinar
cells to undergo cellular de-differentiation where transcription factors involved in
maintaining mature acinar cells are downregulated and transcription factors involved in
promoting ductal gene expression are upregulated. This results in ADM lesions that
express Sox9 and Ck19, which are markers of ADM. This process is necessary for acinar
cell regeneration and re-differentiation once injury is ceased.
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1.6 The unfolded protein response pathway
The UPR signaling pathway plays a pivotal role in the lumen of the ER to prevent
accumulation of misfolded proteins and maintains a homeostatic protein load within the
cell (Ron & Walter, 2007; Kadowaki & Nishitoh, 2013). The concentration of misfolded
proteins can increase due to factors such as genetic mutations, nutritional deprivation of
the cell, hypoxic conditions, changes in pH and temperature (Bernales et al., 2006; Maas
& Diehl, 2015). The UPR responds to the demand of misfolded proteins by increasing the
recruitment of chaperone proteins to misfolded proteins thereby promoting proper folding
or degradation (Liu & Kaufman, 2003; Ron & Walter, 2007; Kadowaki & Nishitoh,
2013). Chaperone proteins such as BiP (member of the heat shock protein HSP70
family), protein disulfide isomerase and glucose-regulated protein 94 (GRP94) are all
responsible for facilitating proper folding of proteins (Ron & Walter, 2007). If the
misfolded protein load still persists, the UPR will quickly attempt to reduce overall global
protein translation or target proteins for degradation by ER-associated degradation
(ERAD). If high misfolded proteins concentration still persists, the UPR will trigger
cellular apoptosis (Liu & Kaufman, 2003; Ron & Walter, 2007; Kadowaki & Nishitoh,
2013). The UPR mechanistically decides the appropriate response by activating three
UPR signalling branches according to the concentration of misfolded proteins within the
cell.

1.6.1 Signal transducers of the UPR pathway
The UPR consists of three signalling branches: double-stranded RNA-activated protein
kinase (PKR)–like ER kinase (PERK), inositol requiring enzyme 1 (IRE1) and activating
transcription factor 6 (ATF6). The two branches that respond immediately to the
deregulation of UPR homeostasis are the PERK and IRE1 branches (Liu & Kaufman,
2003; Ron & Walter, 2007; Kadowaki & Nishitoh, 2013). PERK is activated as a result
of RER transmembrane oligomerization and autophosphorylation. This leads to the
dissociation of chaperone proteins from PERK and the phosphorylation of the α subunit
of translation initiation factor 2 (eIF2α). Phosphorylation of eIF2α results in inactivation
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and inhibition of global mRNA translation, thus reducing protein load in the RER (Ron &
Walter, 2007). However, proteins that have a small 5' open reading frame are
preferentially translated when the ratio of phosphorylated eIF2α exceeds the active form
(Ron & Walter, 2007). One such protein is ATF4. ATF4 targets downstream genes such
as transcription factor C/EBP homologous protein (CHOP) and growth arrest and DNA
damage inducible 34 (GADD34) (Ron & Walter, 2007). GADD34 encodes protein
phosphatases that counteract eIF2α phosphorylation (Ron & Walter, 2007) while CHOP
induces apoptotic cell death. In addition, ATF4 expression induces activating
transcription factor 3 (Atf3) gene expression.
The second branch of the UPR, IRE1, is highly conserved and activated immediately
along with PERK (Liu & Kaufman, 2003). IRE1 is activated as a result of conformational
changes from oligomerization in the ER membrane (Liu & Kaufman, 2003). The
activated form of IRE1 cleaves X-box binding protein 1 (XBP1) giving rise to the spliced
variant of XBP1 (sXBP1) (Liu & Kaufman, 2003; Ron & Walter, 2007). Spliced XBP1
regulates genes that promote ERAD activity (Liu & Kaufman, 2003; Ron & Walter,
2007). The last branch that is activated is the highly conserved ATF6 pathway (Ron &
Walter, 2007). ATF6 relocates to the Golgi apparatus where it is proteolytically cleaved.
The cleaved form translocates to the nucleus where it activates genes that give rise to
chaperone proteins (Ron & Walter, 2007).

1.6.2 The role of the UPR in pancreatic injury
Unlike other cell types, the UPR pathway is active under physiological conditions in
pancreatic acinar cells (Iwawaki et al., 2010), likely due to the high protein turnover rate
in acinar cells (Iwawaki et al., 2010). Deleting Xbp1 causes lethality shortly after birth in
mice as a result of abnormal embryonic pancreatic development (Lee et al., 2005).
Interestingly, with the exception of the pancreas and salivary glands, other organs remain
unaffected in the absence of XBP1 (Lee et al., 2005). Further, ablation of PERK mice
results in pancreatic atrophy after birth along with abnormalities in other organ systems
(Iida et al., 2007). This highlights that the UPR plays a crucial role in normal pancreatic
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function and development compared to other organs. In pathological conditions, such as
pancreatitis, inhibiting one branch of the UPR pathway (IRE1) results in the sustained
activation of the PERK branch suggesting that compensatory mechanisms between the
branches do exist (Lugea et al., 2011). However, ablating Chop results in less severe
pancreatitis in experimental models (Suyama et al., 2008), suggesting that the UPR
pathway can promote pathology in addition to having a physiological role in the
pancreas. To develop additional therapies and detection capabilities for PDAC and
pancreatitis, better understanding of downstream effectors of the UPR pathway is
required.
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Figure 1.4. The Unfolded Protein Response pathway (UPR). The UPR pathway is
activated in response to increasing misfolded protein load that exceeds its capacity to
correctly fold. The UPR has three signalling branches that help correct misfolded proteins
and reduce protein load. The three signalling branches in the UPR includes the doublestranded RNA-activated protein kinase (PKR)–like ER kinase (PERK), inositol requiring
enzyme 1 (IRE1) and activating transcription factor 6 (ATF6). Overall, the three
pathways result in reduced overall protein translation elevating protein load in the ER and
the transcription of genes that are components of the UPR ERAD pathway.
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1.6.3 Role of Activating Transcription Factor 3 in the UPR
ATF3 is a stress response protein downstream of ATF4 within the PERK branch of the
UPR (Jiang et al., 2004; Brooks et al., 2014; Rohini et al., 2018). ATF3 expression is
rapidly induced by cellular stress with maximal expression seen 4 hours into cerulein
treatment (48-fold higher compared to non-injured cells) in pancreatic cells as evident by
mRNA and protein expression (Fazio et al., 2017). The Atf3 gene encodes a 181 amino
acid protein with a molecular mass of 21 kDa (Rohini et al., 2018). ATF3 belongs to the
family of activating transcription factor/cAMP responsive element binding (ATF/CREB)
proteins (Rohini et al., 2018). ATF/CREB proteins are classified as basic leucine zipper
(bZIP) transcription factors that can induce or repress transcriptional activity depending
on ATF3’s binding partner and the gene being targeted (Rohini et al., 2018; Li et al.,
2018). Normally truncated forms of ATF3 do exist (ATFΔZip; 135 amino acids), which
lack the functional bZIP DNA binding element domain (Jiang et al., 2004; Brooks et al.,
2014; Rohini et al., 2018). ATFΔZip has the ability to bind other transcription factors
with a bZIP binding element and influence gene expression (Jiang et al., 2004; Brooks et
al., 2014; Rohini et al., 2018).
In the conical UPR pathway, PERK activation under cellular stress (Bernales et al., 2006;
Maas & Diehl, 2015) signals ATF4 to bind C/EBP-ATF response element (CARE) on the
ATF3 promoter inducing transcription (Hai et al., 1999; Eferl & Wagner, 2003). ATF3
along with ATF4 induces Chop and Gadd34 transcription (Jiang et al., 2004; Han &
Kaufman, 2017). Overexpression of ATF3 can partially bypass the requirement of PERK
activation for the induction of GADD34 as a result of cellular stress (Jiang et al., 2004)
indicating that ATF3 can function indirectly to induce gene expression in the absence of
PERK activation. Additionally, ATF3 can be activated through the IRE1 branch of the
UPR pathway (Liang et al., 1996; Jiang et al., 2004). Phosphorylation of ATF2 and cJUN
as a result of cellular stress mediated by IRE1 can activate ATF3 expression downstream
(Liang et al., 1996; Jiang et al., 2004). Finally, the ATF6 branch of the UPR pathway is
capable of activating ATF3 by binding CARE on the ATF3 promoter (Kowalik et al.,
2007). These findings suggest ATF3 is a central mediator of the pathological response to
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UPR activation. Therefore, ATF3’s role in physiological and stress induced conditions its
transcriptional complexes and targets needs to be better understood.

1.6.4 Transcriptional complexes and targets of ATF3
ATF3 can form a wide array of complexes either as a homodimer or a heterodimer
(Rohini et al., 2018). ATF3 homodimer or in a complex with other proteins is rapid in
inducing or repressing gene transcription upon various stress signals depending on the
target gene (Rohini et al., 2018). The expression of ATF3 alone is capable of repressing
Nrf2 expression, which is responsible for regulating genes involved in the regulation of
free-radical oxygen species (ROS) (Brown et al., 2008). ATF3 represses Nrf2 gene
transcription by directly binding antioxidant response elements (ARE) in the Nrf2
promoter (Brown et al., 2008). Furthermore, Nrf2 repression is significantly more
enhanced by TGF-β mediated ATF3 activation (Brown et al., 2008). Secondly, ATF3 can
complex with p53 and repress expression of matrix metallopeptidase 2 (MMP2) (Yan et
al., 2002). MMP2 is involved in enzymatically cleaving components of the ECM and
molecules involved in signal transduction (Yan et al., 2002; Mo et al., 2010). ATF3 also
has the ability of complexing with mutated p53 and repressing its oncogenic effects (Mo
et al., 2010). Additionally, ATF3 can complex with ATF4 and induce the expression of
phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1) independent of p53
induced PMAIP1 activity to promote apoptotic cell death (Wang et al., 2009).
Along with transcriptional regulation, there is also a role for ATF3 in epigenetic
regulation of chromatin remodelling and gene expression (Li et al., 2016; Cui et al.,
2015). ATF3 complexed with histone deacetylase 6 (HDAC6) is associated with an
increase in chromatin remodelling (Li et al., 2016). Moreover, ATF3 stabilizes and
enhances histone acetyltransferase (HAT) activity, which is involved in transferring
acetyl groups to lysine residues on histones (Cui et al., 2015).
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1.6.5 Role of ATF3 in physiology and pathology
Once induced, ATF3 can affect several signaling pathways including SMAD, ERK, c-Jun
N-terminal kinase (JNK), p38 and NF-κB (Hoetzenecker et al., 2012; Anido et al., 2010;
Wang & Yan, 2016; Guo et al., 2015). These signalling pathways are primarily utilized
by ATF3 to relieve stress by DNA damage repair and cell cycle regulation (Je et al.,
2014). In addition, ATF3 can also bind NF-κB and repress the expression of cytokines
(IL-6, TLR-4) that are activated and secreted as a result of NF-κB signalling (Dawn et al.,
2004; Gilchrist et al., 2006). Further, ATF3 is vital for the migration of neutrophils to
areas of injury to mitigate damage in lung tissue (Boespflug et al., 2014). In contrast, in
skin tissue, ATF3 is critical for negatively regulating cancer-associated fibroblasts
(CAFs) to prevent the excessive deposition of ECM proteins that would otherwise
promote carcinogenesis (Kim et al., 2017).
Under pathological conditions ATF3 acts to promote carcinogenesis or cell death in a cell
type dependent manner (Thompson et al., 2009; Yin et al., 2010; Wu et al., 2010;
Ishiguro et al., 2000). Conflicting roles for ATF3 have been reported for metastatic
prostate cancer (Wang et al., 2015; Bandyopadhyay et al., 2006). In mouse models,
knock-down of ATF3 promotes more aggressive metastatic prostate cancer (Wang et al.,
2015). In contrast, the high expression of ATF3 by androgen stimulation in cell-based
models results in the down-regulation of the anti-metastatic gene (Drg1: developmentally
regulated GTP binding protein 1) (Bandyopadhyay et al., 2006). Similarly, in breast
cancer cell lines and tumours derived from human patient samples, the overexpression of
ATF3, as a result of TGF-β signalling, reduces patient survival and promotes tumour
development and metastasis (Massagué et al., 2000). Further, ATF3 promotes the
expression of runt-related transcription factor 2 (Runx2) in breast cancers allowing for
metastasis to the bone marrow (Vishal et al., 2017). Alternatively, in colon and colorectal
cancers, ATF3 overexpression reduces cell survival by exerting anti-tumorigenic effects
(Song et al., 2016; Kim et al., 2015). In pancreatic cancer, ATF3’s role has not yet been
examined to date.
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1.7 Rationale, hypothesis & objectives
Rationale: PDAC is the most common form of pancreatic cancer with a very low
survival rate (James et al. 2018; Koikawa et al. 2018). In addition to oncogenic KRAS
activation other genetic and environmental factors are needed for full PDAC progression
(Bryant et al., 2014; O’Hagan & Heyer, 2011; James et al., 2018). In a previous study our
lab showed ATF3 was upregulated within hours of inducing acute pancreatitis. That
study found ATF3 directly regulated the ADM process by recruiting histone deacetylase
5 (HDAC5) to the Mist1 promoter to repress gene activation (Fazio et al., 2017). In
addition, ATF3 was shown to directly bind the Sox9 promoter to induce gene activation
and promote ADM development. It is understood that persistent ADM increases the
likelihood of neoplastic transformation which can progress to full blown PDAC (Kopp et
al., 2012). Further, the study identified pathways (RAS, MAPK and Wnt signalling)
linked to pancreatitis severity that could potentially lead to carcinogenesis (Fazio et al.,
2017). Although, this study found a novel role for ATF3 in acute injury, acute
pancreatitis is reversible and remains to be a poor predictor of PDAC (Yadav &
Lowenfels, 2006). Recurrent forms of pancreatitis that have the potential of developing
into CP remains to be the best predictor and susceptibility factor for PDAC development
(Yadav & Lowenfels, 2006; Fagenholz et al., 2007; Krishna et al., 2017; Lew et al.,
2017). To our knowledge the role of ATF3 has not been studied in recurrent forms of
injury nor in the context of oncogenic KRAS, which has the capability of giving rise to
PDAC.
Hypothesis: I hypothesize that ATF3 is required for persistent acinar-to-ductal cell
metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN) in recurrent
pancreatitis and PDAC
Objectives:
1. Determine if the absence of ATF3 affects the severity of recurrent pancreatitis.
2. Determine the requirement of ATF3 for the initiation of oncogenic KRAS-induced
PDAC.
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This thesis will investigate a novel role for ATF3 in recurrent pancreatitis. It will allow
me to determine if ATF3 has a role in recurrent pancreatitis susceptibility or affect on
pancreatic tissue regeneration. Additionally, this thesis will allow me to determine if
oncogenic KRAS bypasses the need for ATF3 in PDAC progression.
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CHAPTER 2
2

METHODS

2.1 Mouse Models
All experiments carried out with mice were approved and handled according to
regulations by the Animal Care and Use Committee at the University of Western Ontario
(protocol #2017-001). Male and female C57/bl6 mice carrying a germline deletion for
Atf3 (Atf3-/-) as described by Hartman et al., 2004 were used for recurrent pancreatitis
studies and compared to C57/bl6 wild-type mice (Atf3+/+) at ages ranging from two-tofour months. In addition, Atf3-/- mice were bred with mice carrying CreERT targeted to a
Ptf1a allele (Ptf1acreERT/+). Ptf1a is an acinar cell-specific gene and creERT allows
inducible deletion through the cre-LoxP system when tamoxifen is present. Atf3-/Ptf1acreERT/+ mice were crossed to mice carrying a constitutively active Kras gene
(KRASG12D) preceded by loxP sites flanking a stop codon (loxP-stop-loxP; LSL) and
targeted to the Kras allele (KrasLSL-G12D/+). Mice lacking Atf3 with Ptf1acreERT/+ and
KrasLSL-G12D/+ (Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+) were experimentally treated and
compared to Atf3+/+ (Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+) mice. Mice lacking oncogenic
Kras with Ptf1aCreERT/+ in the presence (Atf3+/+; Ptf1aCreERT/+) or absence of Atf3
(Atf3-/-; Ptf1aCreERT/+) were used as controls to determine if loss of one Ptf1a allele
affected pancreatic morphology and function. A yellow fluorescent protein (Yfp) knocked
into the Rosa26R (Rosa26RYFP/+) allele was also bred into this line for lineage tracing
origin of lesions. Genotypes were confirmed before and after experimentation using the
primers indicated in Table 2.1.
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2.2 Cerulein Induced Pancreatitis (CIP)
Mice were given normal chow and water ad libitum throughout the experiment. To
induce recurrent pancreatitis, Atf3-/- and Atf3+/+ mice received intraperitoneal injections of
ceruelin (250 µg/kg body weight; Sigma; Cat. #17650-98-5; St. Louis, MO) or 0.9%
saline (control) at 9 AM and 3 PM daily (n = 5-6 per genotype/treatment for both time
points). Cerulein is a CCK analog (Aghdassi et al., 2011). Mice were weighed daily to
determine changes in body weight. 14 days after initiating pancreatitis, cerulein injections
were stopped. Mice were euthanized one or seven days after the last set of injections.
Pancreatic weight (g) was determined post mortem and compared to total body weight.
Table 2.1: DNA primers used for genotyping mice
Gene
Atf3

LSLKrasG12D

Forward

Yfp

Common

5' -

5' -

5' -

TGAAGAAGGTAAACA

ATCAGCCAGCCTCTGTT

AGAGCTTCAGCAATG

CACCGTG

CCAC

GTTTGC

5' -

5' -

5' -

GTCTTTCCCCAGCACA

CTCTTGCCTACGCCACC

AGCTAGCCACCATGG

GTGC

AGCTC

CTTGAGTAAGTCTGCA

5' -

5' -

P48CreERT TCGCGATTATCTTCTA

Rosa26R

Reverse

GCTCGACCAGTTTAGTT

TATCTTCAG

ACCC

5' -

5' -

5' -

GGAGCGGGAGAAATG

GCGAAGAGTTTGTCCTC

AAAGTCGCTCTGAGTT

GATATG

AACC

GTTAT

5' -

5' -

ACATGGTCCTGCTGGA

GCGATGCAATTTCCTCA

GTTC

TTT

To activate creERT and promote KrasG12D expression mice received an oral gavage of
tamoxifen (5 mg/day; Sigma-Aldrich; Cat. #10540-29-1) for 5 days. This produces crerecombination efficiency >95% (Roy et al., 2016). Mice were allowed to rest for 7 days
to recover from the tamoxifen treatment. On days 13 and 15 mice were administered
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cerulein (I.P. injection; 50 µg/kg) 8 times over 7 hours (n = 3-10 per genotype/treatment
at both time points). Mice were weighed to monitor overall health. If body weight
dropped below 15% of their starting weight, mice were sacrificed. Mice were sacrificed
either two or five weeks after cerulein administration and pancreatic tissue collected and
weighed.

2.3 Tissue Fixation & Histology
Pancreatic tissue from the head and tail of the pancreas was harvested, rinsed in PBS and
fixed in 4% formaldehyde in PBS overnight at 4°C. Tissue samples were washed in PBS
for 24 h at 4°C post fixation, then dehydrated and embedded in paraffin. Tissue was
sectioned at 5 µm using a HM325 Rotary Microtome (ThermoFisher Scientific) and
sections rehydrated prior to staining protocols.
To assess histologically and identify differences in pancreatic tissue architecture, sections
were stained with H&E and analyzed. Early neoplastic lesions (ADM) were classified
based on flat cuboidal tubular complexes surrounded by fibrosis and inflammation.
Progressive lesions (PanINs) were graded based on nuclear irregularities, mucinous
epithelium, and dense areas of fibrosis and inflammation surrounding PanIN lesions. In
addition, specific ductal and transcription markers were further used to identity lesions
from healthy tissue.
To assess fibrosis, paraffin sections were stained using a standard Mason’s Trichrome
stain (ab150686; Abcam Inc.). The area staining blue (fibrosis) was identified and
quantified using ImageJ as a percent of total tissue area. Secondly, mucin accumulation
was visualized using an Alcian Blue stain kit (ab150662; Abcam Inc.). The kit targets all
variants of the mucin protein. The total area of blue staining was taken as a percentage of
the whole tissue area.
In all cases, 10-15 images were taken for each sample and from multiple sections that
were at least 200 µm apart using an Aperio CS2 Digital Scanner and Aperio ImageScope
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software (Leica Biosystems Imaging Inc, San Diego, CA, USA) and Leica Microscope
DM5500B (Leica Microsystems, Wetzlar, Germany) with LAS V4.4 software.
To assess recombination efficiency through YFP detection, tissue was fixed in 4%
methanol-free paraformaldehyde for 2 h and incubated at 4°C. Following PBS washes
post fixation, samples were incubated in 30% sucrose overnight at 4°C. Pancreatic tissue
was embedded in cryomatrix (ThermoFisher Scientific) and stored at -80°C for
sectioning. Frozen blocks were allowed to climatize to the cryostat chamber and
sectioned to 6 µm using a Shandon cryostat (ThermoFisher Scientific). YFP expression
was determined by fixing sections with 4% paraformaldehyde. YFP expression was
determined natively without the use of immunostaining. The percent of YFP expression
was determine by calculating the total area positive for YFP over the total tissue area.
Images (8-10 per tissue) were obtained with a Leica Microscope DM5500B DFC365 FX
camera and used for analysis and quantification.

2.4 Immunohistochemistry & Immunofluorescence
Immunohistochemistry (IHC) was performed on paraffin embedded sections using a
Vectastain ABC HRP kit. Sections were rehydrated and then incubated in PBS for 5
minutes before being immersed in working solution (0.1 M Citric Acid Monohydrate, 0.1
M sodium citrate dehydrate in dH2O). For antigen retrieval, sections were heated in a rice
cooker for 45 minutes and cooled to room temperature, then immersed in H2O2 in
methanol for 10 minutes to reduce endogenous peroxidase activity. Sections were
permeabilized with 0.2% Triton-X in PBS for 12 minutes at RT, washed with 0.2%
Tween-20 in PBS, then blocked in 5% sheep serum in PBS for 1 hour at room
temperature. Blocking solution was removed and samples covered in primary antibody
diluted in 5% sheep serum in PBS and incubated overnight at 4°C. Primary antibodies
used included PDX1 (1:1000; Abcam Inc. Cambridge, MA), amylase (1:600; Abcam
Inc.), CK19 (1:500; Abcam Inc.) and MIST1 (1:500; Pin et al., 2000). The next day,
sections were washed in PBS 4X for 5 minutes, then incubated in biotinylated mouse
anti-rabbit IgG secondary antibody (1:1000 dilution in 5% sheep serum) for 30 minutes at
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room temperature. Secondary antibody was removed, and sections washed with PBS 4X.
Sections were incubated in AB reagent for 30 minutes at room temperature. AB reagent
was washed off and ImmPACT DAB Peroxidase (HRP) substrate (Vector Laboratories,
Cat. #PK-4001/SK-4105) used for detection of HRP. DAB substrate was left on sections
until reaction was complete based on visualization with a light microscope. To stop the
DAB reaction, sections were immersed in dH2O. Slides were counterstained with
hematoxylin for 7 seconds and washed with dH2O for 1 minute. Counterstained slides
were dehydrated in increasing ethanol concentration before being incubated in xylene.
Slides were covered with permount and coverslip and imaged using Leica Microscope
DM5500B (Leica Microsystems) and LAS V4.4 software.
Immunofluorescence analysis (IF) was performed on paraffin embedded tissue sections
similar to the IHC. The same IHC protocol was followed with the exception of the H2O2
in methanol step. Primary antibodies used included: SOX9 (rabbit, 1:250; Millipore
Sigma), Ki67 (rabbit, 1:250; Abcam Inc.) and F4/80 (rat, 1:200; Abcam Inc.). Slides
were washed 4 times for 10 minutes and immersed in secondary antibody conjugated to a
TRITC (1:300; Jackson ImmunoResearch, West Grove, PA) or FITC (1:300; Jackson
ImmunoResearch) fluorophore protein for 1 hour at room temperature. Secondary
antibody was removed, and sections washed 4X times with PBS and then in DAPI
(diluted 1:1000 in PBS; Thermo Fisher Scientific) for 5 minutes at room temperature.
DAPI was removed, slides mounted with Vectashield Permafluor mountant (Thermo
Fisher Scientific) and imaged using Leica DFC365 FX camera on the Leica DM5500B
microscope. Images were taken on Leica LAS V4.4 software.

2.5 Protein Isolation & Immunoblots
Pancreatic tissue was taken from the middle portion of the pancreas and flash frozen in
liquid nitrogen and stored at -80°C. Samples were homogenized in protein isolation
buffer on ice. Protein isolation buffer consisted of 5 mM MgCl2, 50 mM Tris pH 7.2, 10
mM DTT, 1 mM CaCl2, 1% NP-40, RNAse A (50 µg/ml), DNAse (100 units/ml), 1 mM
PMSF, 30 mM NaF, 2 mM Na3VO4 and 5 µg/ml of each protease inhibitors: leupeptin,
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aprotinin and pepstatin. Samples were kept on ice and sonicated for 20 seconds and
centrifuged at 5000 x g for 5 minutes at 4°C. The supernatant was collected, and the
pellet discarded. Protein concentration was determined using Bradford Assay dye
(BioRad, Mississauga, ON) as per manufacturer’s instructions.
Loading dye was added to either 2 µg (for amylase analysis) or 40 µg of protein (SOX9,
pERK and aSMA) and incubated at 95°C for 5 minutes. Denatured protein samples were
resolved by a 12% SDS-PAGE at 200 volts and transferred to PVDF membrane (200
mV, 90 minutes). Following transfer, blots were incubated in 5% NFDM for 1 hour at
room temperature. Blots were washed once in TBS, then incubated in primary antibodies
diluted in 0.1% TBST with 5% BSA. Primary antibodies included rabbit antiphosphorylated ERK (diluted 1:500) and rabbit anti-total ERK (1:500) (Cell Signaling
Technology, Danvers, MA). In some instances, primary antibody was incubated in 5%
NFDM overnight at 4°C (rabbit anti-amylase [1;1000]; rabbit anti-SOX9 [1:500]; rabbit
anti-αSMA [1:500]), in which case TBS washes after blocking were omitted. Following
primary antibody incubation, blots were washed 4 x 5 minutes with TBS, then incubated
in secondary antibody (anti-rabbit HRP, diluted 1:10,000 in 5% NFDM; Jackson Labs)
for 1 hour at room temperature. Blots were washed 4 times with TBS, then incubated in
Western ECL (Bio-Rad) substrate for 1 minute before being imaged on a VersaDoc
system with Quantity One analysis software (Bio-Rad). Blots were quantified using
densitometry on ImageJ and normalized to tERK expression.

2.6 Statistical Analysis
Data was analyzed using a Student’s t-test (unpaired, two-tailed), one-way ANOVA or
two-way ANOVA with a Tukey’s post hoc test on GraphPad Prism 6 software. Statistics
used for weight loss over time was a repeated measures two-way ANOVA with a
Tukey’s post hoc test. Data is shown with individual samples and error bars representing
the mean ± standard error (SE). P value <0.05 was considered significant.
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CHAPTER 3
3

RESULTS

3.1 The absence of ATF3 reduces ADM and improves tissue regeneration in
mice undergoing recurrent pancreatic injury
To determine if ATF3 was required for change in cell differentiation in response to
pancreatic injury, a cohort of wild type and Atf3-/- mice were subjected to recurrent
pancreatitis (RP) using CIP for two-weeks (14 days). Pancreatic tissue was collected on
days one and seven following cessation of cerulein treatment to assess tissue damage and
regeneration (Figure 3.1A). The percent change in body weight in WT and Atf3-/- mice
after undergoing RP showed no significant difference between WT and Atf3-/- genotypes.
However, both genotypes undergoing RP showed significant weight loss compared to
saline treated genotypes (Figure 3.1B). Upon dissection one day after cerulein cessation,
WT and Atf3-/- mice had significantly smaller pancreata compared to saline treated mice
(Figure 3.2A). However, no difference in percent pancreatic weight relative to body
weight was seen between WT and Atf3-/- CIP treated mice at this time point. Seven days
after post RP recovery, CIP-treated Atf3-/- mice had a significantly higher percent
P.W./B.W. ratio compared to CIP-treated WT mice (Figure 3.2A). In fact, percent Atf3-/CIP P.W./B.W. ratios were statistically similar to saline treated Atf3-/- pancreatic weight
seven days after the cessation of cerulein treatment. In contrast, WT CIP treated
pancreata remained small compared to WT saline treated mice after recovery.

To determine the extent of injury in WT and Atf3-/- mice, pancreatic tissue sections were
assessed by histological staining. H&E staining of pancreatic tissue from WT and Atf3-/CIP-treated mice revealed significantly more putative ADM (based on cuboidal
morphology of cells) compared to saline treated mice one- and seven-day following CIP
(Figure 3.2B and C). No significant differences in the number of putative ADM per unit
area was seen between WT and Atf3-/- CIP treated mice on day one; however,
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significantly fewer putative ADM was observed in CIP-treated Atf3-/- mice compared to
CIP-treated WT mice seven days into recovery (Figure 3.2C). Next, the severity of
fibrosis was determined using Mason’s Trichrome stain. No significant differences in
fibrosis area was seen between the genotypes one or seven days after CIP treatment
(Figure 3.3), although overall fibrosis was reduced by day seven compared to day one in
both genotypes.
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Figure 3.1. Atf3-/- mice show no significant difference in body weight compared to
WT mice undergoing RP. (A) A schematic timeline showing the treatment regimen
used and the dates when mice were sacrificed. (B) Both WT and Atf3-/- mice (n = 11-21)
that received cerulein lost significant body weight compared to mice that received saline
(*P<0.05, **P<0.005, ****P<0.0001) starting from day 4 to day 14. However, no
significant difference in body weight was seen between the genotypes in the cerulein
treated group (P>0.05). The black arrows indicate when mice were sacrificed. The error
bars represent mean ± SE; A repeated measures Two-way ANOVA with a Tukey’s post
hoc test was performed.
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Figure 3.2. Atf3-/- mice show pancreatic tissue regeneration and a lower putative
ADM count after the cessation of RP. (A) Percent pancreatic weight relative to body
weight. On day one post RP, there was a significant decrease in pancreatic weight in both
genotypes treated with cerulein compared to the genotypes receiving saline (WT;
*P<0.05, Atf3-/-; **P<0.005; n = 6-7). No significant difference in pancreatic weight was
seen between the genotypes in the cerulein treated group after the immediate cessation of
RP. Following seven days of RP cessation, Atf3-/- mice showed a significant increase in
pancreatic weight compared to WT mice (*P<0.05). However, WT CIP pancreata
remained small compared to WT saline treated tissue (****P<0.0001) while tissue
lacking ATF3 was comparable in pancreatic weight to Atf3-/- saline treated tissue (P>0.05;
n = 4-6; % mean ± SE shown). (B) Representative H&E shows loss of healthy acinar
tissue in both genotypes and a significant increase in putative ADM one day after RP in
both genotypes, black arrowhead points to putative ADM. (C) There was significantly
less putative ADM in Atf3-/- mice after seven days of RP compared to WT mice in the
CIP group (*P<0.05; n = 4-6; mean ± SE shown). The black bar represents 200 µm while
the white bar represents 50 µm. A two-way ANOVA with a Tukey’s post hoc test was
performed.
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Figure 3.3. The absence of ATF3 does not alter fibrosis. (A) Representative images
showing Mason’s Trichrome stain used to detect collagen as a measure of fibrosis (black
arrow points to collagen deposits; n = 4-6). (B) RP induced significant fibrosis one-day
post injury cessation in both genotypes compared to saline treated mice (Atf3-/-;
**P<0.005, WT; ****P<0.0001). No significant difference in fibrosis was seen between
WT and Atf3-/- CIP treated mice on day one post CIP. Following seven days of recovery,
percent fibrosis was comparable between saline and CIP treated groups. The white bars
represent 50 µm. % mean ± SE shown. A two-way ANOVA with a Tukey’s post hoc test
was performed.
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Histological (H&E) analysis suggested Atf3-/- mice have greater tissue regeneration in
response to recovery post RP. This was further supported by molecular markers of ADM.
Immunohistochemistry staining for CK19, a marker of ductal cells, showed significantly
more CK19+ cells in WT mice compared to Atf3-/- mice both one (Figure 3.4A and B)
and seven days following CIP treatment. Analysis for amylase, a marker of acinar cells,
showed no difference one day post recovery, but was significantly higher in Atf3-/- mice
compared to WT mice after seven days of recovery based on IHC (Figure 3.4C) and
immunoblotting (Figure 3.4D and E). The expression of amylase protein was 2.4 ± 1.76fold higher in Atf3-/- tissue compared to WT tissue after seven days of recovery post RP
(Figure 3.4E).
To better understand the ADM process in RP and recovery, specific transcription factors
involved in the ADM development program were examined by IHC and IF. MIST1 is a
transcription factor that is needed to maintain the mature acinar cell phenotype (Pin, et
al., 2001). IHC revealed significantly more MIST1+ nuclei (black arrowhead) in Atf3-/tissue compared to WT tissue one day following cessation of RP (Figure 3.5A and B). In
addition, many putative ADM lesions in Atf3-/- tissue expressed MIST1 (white
arrowhead) while putative ADM lesions seen in WT tissue were found to be MIST1
negative. Seven days following recovery, no significant differences in MIST1 expression
was seen between cerulein treated Atf3-/- and WT mice (Figure 3.5A and B). To
determine if transcription factors involved in ADM formation and maintenance was
affected in the absence of ATF3 we evaluated SOX9 and PDX1 expression (Kopp et al.,
2011; Roy et al., 2016). Immunoblotting for SOX9 showed no detectable protein
expression in Atf3-/- tissue one or seven days following CIP (Figure 3.5C). IF analysis
confirmed significantly fewer SOX9+ cells at both time points (Figure 3.5 D and E).
Similar to SOX9 expression, PDX1 was expressed in significantly fewer ADM and
acinar cells in Atf3-/- tissue compared to WT tissue (Figure 3.5 F and G).
To determine if cellular proliferation was also affected in the absence of ATF3, Ki67
immunofluorescence was performed (Figure 3.6). The percent Ki67+ cells were
significantly higher in Atf3-/- tissue one day after the cessation of RP compared to WT
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mice that underwent RP (Figure 3.6B). Following seven days of recovery there was a
significant reduction in proliferation in Atf3-/- tissue compared to WT tissue.
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Figure 3.4. Atf3-/- tissue shows reduced duct marker staining and increased digestive
enzyme accumulation. (A) IHC for the duct marker CK19 shows a reduction in
cytoplasmic staining in the absence of ATF3 compared to WT tissue at both days one and
seven post CIP. (B) Quantification of representative IHC images for CK19 confirms a
significant reduction in percent area staining for CK19 in Atf3-/- tissue compared to WT
tissue at both experimental time points (**P<0.005; n = 4-5; % mean ± SE; a two-way
ANOVA with a Tukey’s post hoc test was performed). (C) Representative IHC for
amylase shows enzyme accumulation seven days following recovery in Atf3-/- tissue
compared to WT tissue. (D) Representative Western blot shows increased amylase
protein accumulation in the Atf3-/- tissue compared to WT tissue following seven days of
recovery. (E) Relative protein expression was quantified using densitometry and
normalized to tERK expression. Significantly more amylase accumulation was observed
in the absence of ATF3 compared with WT tissue on day seven following RP (Atf3-/-;
*P<0.05; n = 4-6; mean ± SE; a two-way ANOVA with a Tukey’s post hoc test was
performed).
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Figure 3.5. ATF3 affects the expression of transcription factors involved in ADM
during RP. (A) The expression of MIST1 (IHC) was maintained one-day post cessation
of injury in Atf3-/- tissue compared to WT. The expression of MIST1 in both WT and
Atf3-/- cerulein treated tissue was comparable to the saline treated genotypes by day seven
post recovery. Black arrows point to MIST1 negative nuclei. White arrows point to
putative ADM. Black arrowheads point to MIST1 positive nuclei. (B) Quantification of
MIST1 supported this finding (day one: Atf3-/-; *P<0.05, WT; ***P<0.005, day seven:
P>0.05, n = 4-5; % mean ± SE; a two-way ANOVA with a Tukey’s post hoc test was
performed). (C) Representative Western blot shows no SOX9 protein expression in Atf3-/tissue at both experimental time points compared to WT tissue. (D) Representative IF
images confirm findings seen in Western blot and show fewer SOX9 positive nuclei in
Atf3-/- tissue at both time points (outlined by white dashes). (E) Quantification of
representative IF images confirm a reduction in the percent of nuclei positive for SOX9
in the absence of ATF3 at both time points (**P<0.005; ***P<0.0005; n = 3; % mean ±
SE; a two-way ANOVA with a Tukey’s post hoc test was performed). Similarly, the
percent of nuclear PDX1 staining was significantly reduced in the Atf3-/- tissue at both
time points (F, G; **P<0.005; n = 3; % mean ± SE; a two-way ANOVA with a Tukey’s
post hoc test was performed). White arrowheads point to PDX1 positive nuclei, both
black and white bars represent 50 µm.
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Figure 3.6. Proliferation is altered during RP in the absence of ATF3. (A)
Representative IF images show significantly more percent positive nuclei for Ki67 in the
absence of ATF3 one-day post CIP. After seven days of post CIP recovery the percent of
nuclear staining was reduced in the absence of ATF3. White arrowheads represent Ki67
positive nuclei. (B) There was a significant increase in the number of positive nuclei for
Ki67 in Atf3-/- tissue on day one compared to WT tissue (**P<0.005). On day seven, the
percent of Ki67 positive nuclei was significantly reduced in the absence of ATF3
compared to WT tissue (***P<0.0005; n=4-5). Error bars represent mean ± SE; a twoway ANOVA with a Tukey’s post hoc test was performed). White bars represent 50 µm.
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3.2 Mice lacking ATF3 show reduced high grade PanIN lesions following
the activation of oncogenic KRAS
My analysis of Atf3-/- mice indicated that ATF3 is required for ADM in recurrent
pancreatitis suggesting it may also be required for ADM associated with initial stages of
PDAC. However, it is possible that oncogenic KRAS can bypass this requirement. To
answer this question Atf3-/- mice allowing for inducible activation of constitutive KRAS
were used following the induction of cerulein-induced pancreatitis (Atf3-/-; Ptf1acreERT/+;
KrasLSL-G12D/+) (Figure 3.7A). CreERT driven by Ptf1a was activated specifically in
acinar cells by tamoxifen administration which led to oncogenic Kras activation.
Following oncogenic Kras activation, mice underwent acute CIP to induce Atf3
expression. Tissue was collected at weeks two and five post injury (Figure 3.7B). The
reporter gene YFP was also bred into Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ line and
indicated extensive cre-recombination (97.98 ± 0.17% creERT-efficiency) had taken
place in acinar cells following treatment with tamoxifen (Figure 3.7C). During TX
treatment and acute CIP, mice were weighed daily. All saline-treated mice, regardless of
ATF3 expression or oncogenic KRAS activity gained body weight over the experimental
time period (Figure 3.8A). However, Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ mice that
underwent CIP had a significant reduction in body weight compared to Atf3+/+;
Ptf1acreERT/+; KrasLSL-G12D/+ and control Atf3+/+; Ptf1aCreERT/+ and Atf3-/-; Ptf1aCreERT/+
mice treated with cerulein. Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ mice had significantly
reduced body weight on days 43 and 50 compared to Atf3+/+; Ptf1acreERT/+ and Atf3-/-;
Ptf1aCreERT/+ mice.
Mice were sacrificed two- and five-weeks post-CIP and pancreatic tissue was collected
for histological and biochemical analysis. Upon dissection, the pancreas was visually
examined to determine if any visible changes occurred gross morphologically between
genotypes and treatment groups. Multiple fibrotic nodules were present only in Atf3+/+;
Ptf1acreERT/+; KrasLSL-G12D/+ pancreatic tissue treated with ceruelin at both time points,
while Atf3-/; Ptf1acreERT/+; KrasLSL-G12D/+ mice had pancreata that appeared visually small
with no nodules were present (Figure 3.8C). To quantify visual difference in pancreatic
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size, the pancreas was weighed and measured as percent weight relative to body weight
(Figure 3.8D). No significant differences in pancreatic weight was observed between
saline-treated genotypes at either experimental time point. However, Atf3+/+;
Ptf1acreERT/+; KrasLSL-G12D/+ mice treated with ceruelin had significantly increased
pancreatic weight as a ratio to total body weight when compared to other saline and
cerulein treated groups at week two post CIP. At week five, Atf3-/-; Ptf1acreERT/+; KrasLSLG12D/+

pancreatic tissue was significantly smaller compared to genotypes in both treatment

groups at week two and remained small up to week five. Overall, Atf3-/-; Ptf1acreERT/+;
KrasLSL-G12D/+ mice lost significant body weight and showed an atrophied pancreas at both
experimental time points.
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Figure 3.7. KRAS-(G12D) is specifically activated in acinar cells of Atf3-/;
Ptf1acreERT/+; KrasLSL-G12D/+ mice. (A) Schematic of mouse model used for
experimentation. (B) Different mouse lines used for experimentation along with the
timeline used in this experiment. (C) Fluorescence images of YFP show expression
specially in acinar cells following cre-recombination induced by tamoxifen
administration. The black arrows point to YFP negative blood vessels. The white
magnification bars represent 100 µm.
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Figure 3.8. Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ mice lose body weight and show an
atrophied pancreas. (A) Percent change in body weight shows no difference between
the four genotypes treated with saline (n = 4-5; % mean ± SE). Significant body weight
loss is observed in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ mice compared to Atf3+/+;
Ptf1acreERT/+; KrasLSL-G12D/+ and control Atf3+/+; Ptf1acreERT/+ and Atf3-/-; Ptf1acreERT/+ mice
that underwent pancreatitis (*P<0.05; ****P<0.0001; n = 5-6; % mean ± SE; a repeated
measures Two-way ANOVA with a Tukey’s post hoc test was performed), black arrows
point to sacrifice time points. (B) Representative images of pancreatic gross morphology
(pancreas highlighted by the dotted white line; S = spleen, L = liver, K = kidney, St =
stomach and Du = duodenum) and their associated genotypes at week two. Atf3+/+;
Ptf1acreERT/+; KrasLSL-G12D/+ mice showed nodular spots on the pancreas (white
arrowheads), while Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+genotypes had smaller pancreata
compared to control mice lacking oncogenic KRAS. (C) Quantification of pancreatic
weight as a percent relative to body weight. Week two post CIP, Atf3+/+; Ptf1acreERT/+;
KrasLSL-G12D/+ mice show a significant increase in pancreatic weight compared to Atf3+/+;
Ptf1acreERT/+; KrasLSL-G12D/+ mice treated with saline (****P<0.0001). By week five,
Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ genotypes treated with CIP were comparable
genotypes treated with saline. Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ pancreata was
significantly small compared to mice in both saline and CIP treated groups at week two
(****P<0.0001). The pancreas of Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ mice remained small
by week five post CIP (*P<0.005, n = 3-5; error bars represent % mean ± SE). Three
Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ mice and one Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+
mouse died during experimentation.
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I next determined if the gross morphological size differences observed was explained by
histological differences. Pancreatic tissue was analyzed using H&E stain to determine
lesion grade (See Appendix 2 for classification of lesions). Samples for each genotype
were grouped based on highest grade lesion present per tissue area. In the saline treated
groups, the absence of oncogenic KRAS resulted in no damage both in the presence or
absence of ATF3 within two weeks of CIP (Figure 3.9). Saline-treated Atf3+/+;
Ptf1acreERT/+; KrasLSL-G12D/+ mice showed greater incidences of focal PanIN1 lesions
compared to incidences of focal ADM seen in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ mice by
week two post CIP (Table 3.1). By week five, saline-treated Atf3+/+; Ptf1acreERT/+;
KrasLSL-G12D/+ tissue persistently showed more PanIN1 and PanIN2 lesions compared to
Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+, which varied from being normal to having focal
regions that showed PanIN2 lesions. Alternatively, Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+
and Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ mice treated with cerulein showed higher grade
PanIN3 lesions within two weeks of CIP (Figure 3.10A). However, by week five, Atf3-/-;
Ptf1acreERT/+; KrasLSL-G12D/+ tissue showed predominately lower grade PanIN1 and 2
lesions compared to the PanIN3 and PDAC lesions scored in Atf3+/+; Ptf1acreERT/+;
KrasLSL-G12D/+ tissue (Table 3.2). This finding was further supported by significantly
more mucin accumulation seen in lesions in Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ tissue
compared to Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ mice based on Alcian blue accumulation
(Figure 3.10B and C). In summary, histological lesion scores showed reduced
incidences of high grade PanIN lesions in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue
compared to Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ tissue post five weeks after CIP.
The findings from the histological lesion scores were surprising given the gross
morphological assessment showed small pancreatic tissue with no nodules in Atf3-/-;
Ptf1acreERT/+; KrasLSL-G12D/+ mice compared to Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ mice.
One possibility is that the lesions are the result of duct expansion in Atf3-/-; Ptf1acreERT/+;
KrasLSL-G12D/+ mice and acinar transformation in Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+
mice. To determine if the PanIN lesions are derived from acinar tissue, I performed
lineage tracing analysis and showed PanIN lesions were of acinar cell origin in both
genotypes (Figure 3.11A). However, the percent of YFP+ lesions in Atf3-/-; Ptf1acreERT/+;
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KrasLSL-G12D/+ tissue was significantly lower (22.76 ± 4.91%) compared to Atf3+/+;
Ptf1acreERT/+; KrasLSL-G12D/+ tissue (45.84 ± 7.73%) (Figure 3.11B). Duct-like cells that
did not express YFP were more frequently seen in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+
tissue (black arrowhead) suggesting these cells were not derived from acinar tissue. IHC
analysis done for a duct cell-specific marker cytokeratin 19 (CK19) (Figure 3.11A and
B) indicated the amount of accumulated lesions was significantly lower in Atf3-/-;
Ptf1acreERT/+; KrasLSL-G12D/+ tissue compared to Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ at
both time points (Figure 3.11C). It is also possible that acinar cells are transforming in
Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ mice but not proliferating; Atf3-/-; Ptf1acreERT/+;
KrasLSL-G12D/+ tissue showed significantly fewer proliferative cells based on Ki67 staining
compared to Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ tissue at week two post injury (Figure
3.11D and E). Surprisingly, by week five, proliferation in Atf3-/-; Ptf1acreERT/+; KrasLSLG12D/+

tissue was negligible and statistically comparable to saline treated genotypes. These

results showed Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue had reduced YFP+ lesions, lower
duct cell accumulation along with reduced proliferation compared to Atf3+/+;
Ptf1acreERT/+; KrasLSL-G12D/+ tissue.
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Figure 3.9. The absence of ATF3 reduces high grade PanIN lesions in mice
expressing oncogenic KRAS. Representative H&E images shown. Two weeks after the
induction of pancreatitis Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ pancreata showed more
incidences of higher grade PanIN1 lesions (white arrowhead) compared to ADM
(represented by the asterisk symbol) seen in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ mice. Five
weeks post CIP, the incidence of PanIN2 (black arrowhead) lesions were more frequent
in Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ mice compared to Atf3-/-; Ptf1acreERT/+; KrasLSLG12D/+

mice. Black bars represent 200 µm; white bars represent 50 µm.
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Figure 3.10. Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ mice treated with cerulein show
reduced incidence of high-grade lesions later at week five post CIP. (A)
Representative H&E images show both Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ and Atf3-/-;
Ptf1acreERT/+; KrasLSL-G12D/+ with high grade PanIN3 lesions (indicated by the black
arrowheads) at two weeks post CIP treatment. At week five post CIP, Atf3-/-;
Ptf1acreERT/+; KrasLSL-G12D/+ mice show lower incidences of high grade PanIN3 lesions
and no PDAC compared to Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ mice. Black arrow points
to lower grade PanIN2 lesion. White scale bar represents 50 µm; black scale bars
represents 200 µm. (B) Representative images of Alcian blue showed a higher percent
area stained for mucin in the Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ mice compared to Atf3-/; Ptf1acreERT/+; KrasLSL-G12D/+ mice. Black scale bars represent 400 µm. (C) The
quantification of percent area stained Alcian blue showed a 3-fold decrease in Atf3-/-;
Ptf1acreERT/+; KrasLSL-G12D/+ tissue at week two post CIP (***P<0.001; % mean ± SE; n =
3-4; a One-way ANOVA with a Tukey’s post hoc test was performed).
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Figure 3.11. Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ mice show significantly less lesion
accumulation and fewer proliferative cells. (A) The YFP reporter shows specific
recombination in pancreatic acinar cells (white arrow points to an islet). Upon pancreatic
injury, lesions in both Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ and Atf3-/-; Ptf1acreERT/+;
KrasLSL-G12D/+ tissue expressed YFP (black arrowhead points to ductal structure not
expressing YFP). Magnification bars represent 50 µm. (B) The quantification of YFP
expression as a percent area of the tissue cross section showed 97.98 ± 0.17% crerecombination efficiency in both Atf3+/+; Ptf1acreERT/+ and Atf3-/-; Ptf1acreERT/+ mice that
received saline. There was a significant reduction in YFP expression in Atf3-/-;
Ptf1acreERT/+; KrasLSL-G12D/+ tissue compared to Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ tissue
(*P<0.05; % mean ± SE; n = 3; a One-way ANOVA with a Tukey’s post hoc test was
performed). (C) Representative IHC images show fewer CK19+ lesions in Atf3-/-;
Ptf1acreERT/+; KrasLSL-G12D/+ mice both at weeks two and five post CIP. Magnification bars
represent 500 µm. (D) Representative IF images for Ki67 show a significant decrease in
the percent of Ki67+ nuclei in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue compared to
Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ at both time points. White arrowheads indicate Ki67+
nuclei. Magnification bars represent 100 µm. (E) Quantification of Ki67 at both time
points **P<0.001, ****P<0.0001; error bars represent % mean ± SE; n = 3-4; Two-way
ANOVA with a Tukey’s post hoc test was performed).
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To determine if the decreased amount of duct-like tissue is reflective of reduced ADM, I
next examined pancreatic cell-specific markers, and transcription and signalling factors
involved in ADM. Immunoblots for amylase, a marker of acinar cells, showed no
detectable accumulation in Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ and Atf3-/-; Ptf1acreERT/+;
KrasLSL-G12D/+ tissue post CIP treatment (Figure 12A) suggesting acinar tissue is
completely lost in both genotypes compared to genotypes treated with saline. In contrast,
immunoblots revealed less SOX9 accumulation in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+
pancreatic tissue at two and five weeks post pancreatic injury. SOX9 protein expression
was 7.99 ± 1.24-fold lower in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue compared to
Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ tissue at week two post CIP and 2.58 ± 1.41-fold
lower at five weeks post CIP (Figure 12C). Next, I examined MAPK signalling
downstream effector pERK by performing immunoblot analysis. Reduced pERK
accumulation was observed in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue at two (2.21 ±
0.66-fold less pERK) and five weeks (2.42 ± 0.25-fold less pERK) after injury compared
to Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ tissue (Figure 12D). Further, contrary to the SOX9
immunoblots, IF analysis for SOX9 showed no difference in the number of SOX9+ nuclei
in Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ and Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue at
week two post CIP (Figure 12E and F). Although there may be no difference in the
number of nuclei staining for SOX9 between the two genotypes, it is however possible
that the amount of lesions based on SOX9 accumulation is lower in Atf3-/-; Ptf1acreERT/+;
KrasLSL-G12D/+ tissue at week two. Conversely, by week five post CIP-treatment,
significantly fewer SOX9+ nuclei were observed in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+
tissue compared to Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ tissue. Combined, these results
suggest that the absence of ATF3 in the presence of oncogenic KRAS reduces the
expression of markers involved in ADM and PanIN lesion development.
Since several non-acinar cell types contribute to the pancreatic pathology observed in
PDAC, including stromal cells and immune cells, I determined if the absence of ATF3
leads to altered accumulation of these cells in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ mice.
Fibrosis, as determined by Mason’s Trichrome stain, was significantly more pronounced
two weeks post injury in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue compared to Atf3+/+;
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Ptf1acreERT/+; KrasLSL-G12D/+ tissue (Figure 13A and B). However, immunoblots for
smooth muscle actin-α, a marker of activated stellate cells, showed no significant
difference between Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ and Atf3-/-; Ptf1acreERT/+; KrasLSLG12D/+

tissue at either time point post injury (Figure 13C and D). By five weeks post CIP-

treatment there was no significant difference in fibrosis between and Atf3+/+;
Ptf1acreERT/+; KrasLSL-G12D/+ and Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue. This suggests
that stellate cell function, but not accumulation, may be affected by the absence of ATF3.
Next, to profile the immune system in the absence of ATF3, macrophage infiltration was
assessed by IF for F4/80 (macrophage marker). My findings showed significantly fewer
macrophages in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue five weeks after injury (Figure
14A and B). These results suggest that the loss of ATF3 in the context of oncogenic
KRAS may have a role in both acinar and non-acinar cells.
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Figure 3.12. SOX9 expression and pERK accumulation are significantly reduced in
Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ pancreatic tissue. (A) Amylase was not detectable in
either Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ and Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue
after injury compared to saline-control tissues. (B) Quantification of amylase confirmed
no significant difference between Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ and Atf3-/-;
Ptf1acreERT/+; KrasLSL-G12D/+ tissue post injury (% mean ± SE; n = 3-6; P>0.05).
Representative Western blots show reduced to no detectable SOX9 and pERK expression
in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue compared to Atf3+/+; Ptf1acreERT/+; KrasLSLG12D/+

at two- and five-weeks post CIP. Quantification of SOX9 and pERK (C and D)

confirmed significantly lower protein levels in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue
at both time points compared to controls (Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+; *P<0.05,
**P<0.001; n = 3-6; Two-way ANOVA with a Tukey’s post hoc test was performed). (E)
Shows representative IF images of SOX9 expression in both Atf3+/+; Ptf1acreERT/+;
KrasLSL-G12D/+ and Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ genotypes at weeks two and five
post CIP. Magnification bars represent 50 µm. (F) Quantification of SOX9 positive
nuclei showed no significant difference within two weeks post CIP between Atf3+/+;
Ptf1acreERT/+; KrasLSL-G12D/+ and Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue (p=0.09).
However, five weeks post CIP, significantly fewer SOX9+ nuclei were observed in Atf3-/-;
Ptf1acreERT/+; KrasLSL-G12D/+ tissue compared to Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ tissue
(*P<0.05; n = 3-4; Student’s t-test, unpaired, two-tailed analysis performed).
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Figure 3.13. Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ mice display increased fibrosis at two
weeks point after pancreatic injury. (A) Representative images for fibrosis in Atf3-/-;
Ptf1acreERT/+; KrasLSL-G12D/+ tissue compared to Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ twoand five-weeks post-CIP using Mason’s Trichrome stain kit (black arrow points to
fibrosis), magnification bars represent 50 µm. (B) Quantification of fibrosis (% area
staining blue) shows significant higher levels in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue
compared to Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ at two weeks post CIP (****P<0.0001;
% mean ± SE; n = 3-5). No significant difference was seen at week five post CIP between
the two genotypes. A One-way ANOVA, Tukey’s post hoc test was performed. (C) and
(D) Western blot for αSMA shows no significant difference between cerulein treated
Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ and Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ genotypes at
both time points (n = 3; mean ± SE; n = 3; A Two-way ANOVA, Tukey’s post hoc test
was performed).
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Figure 3.14. Macrophage infiltration is significantly reduced in Atf3-/-; Ptf1acreERT/+;
KrasLSL-G12D/+ tissue compared to Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+. (A and B)
Representative IF images show significantly fewer macrophages in Atf3-/-; Ptf1acreERT/+;
KrasLSL-G12D/+ tissue compared to Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ five weeks postinjury (**P<0.005, % mean ± SE; n = 3). White arrow points to F4/80 staining, which is
a surface marker. Student’s t-test, unpaired, two-tailed analysis performed.
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CHAPTER 4
4

DISCUSSION

4.1 General Overview of Findings
In this study, ATF3 was identified to play a critical role in recurrent pancreatic (RP)
injury and progression to PDAC. The lack of ATF3 expression in pancreatic tissue during
recovery post-RP resulted in increased tissue regeneration. Further, in the context of
oncogenic KRAS, the loss of ATF3 resulted in smaller pancreata and less high grade
PanIN lesions. Molecular markers for pancreatic lesions supported a requirement for
ATF3 for complete and persistent ADM. Ultimately, these results suggest the potential
for directly targeting and inhibiting ATF3 in the pancreas to reduce injury and reduce
high grade PanIN lesions, which could potentially develop into PDAC.

4.2 General Discussion
4.2.1 Role of ATF3 in RP tissue regeneration
To understand PDAC initiation and progression, it is critical to understand the
development of early precancerous lesions such as ADM. A previous study done in our
lab examined and characterized ATF3’s role, but only in acute pancreatitis (Fazio et al.,
2017), which is not a predictor of PDAC (Yadav & Lowenfels, 2006). The study showed
that loss of ATF3 was detrimental to the pancreas early in injury, however, significantly
more pancreatic tissue regeneration along with reduced ADM was seen 72-hours post
injury in the absence of ATF3. The work presented in this thesis utilized similar
methodologies to examine ATF3’s role in RP, which is a significant risk factor for PDAC
(Guda et al., 2018; Yadav & Lowenfels, 2013). My findings demonstrated no difference
in overall lesion formation (fibrosis, inflammation, and ADM) after the immediate
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cessation of RP, suggesting that the lack of ATF3 may not affect early susceptibility to
injury based on H&E analysis alone. However, the lack of ATF3 did improve tissue
regeneration in RP based on findings seen seven days after cessation of RP. These
findings support our previous work on ATF3 in the context of acute pancreatitis.
Therefore, it is possible that the lack of ATF3 is playing a vital role by increasing the
regenerative capacity of progenitor-like cells allowing for re-differentiation of ADM to
acinar cells both in acute injury and RP during the regenerative phase. It is also possible
that ATF3 is further signalling cells to a ductal cell fate, thus, preventing the increased redifferentiation of duct cells back to acinar cells during recovery. This raises the question
of how ATF3 is capable of maintaining the ADM program making possible for further
lesion progression and increasing susceptibility for PDAC development.

4.2.2 Regulation of intrinsic signalling factors in RP
During pancreatic injury, intrinsic factors that normally function to maintain the acinar
cell phenotype are down-regulated and factors that promote the development of ADM are
up-regulated (Park et al., 2011; Miyatsuka, 2006; Shi et al., 2013; Liou et al., 2013).
Subsequently, the cells de-differentiate and take on a progenitor-like state which act to
propagate and re-differentiate back to acinar cells in the absence of injury to cope for
tissue loss (Liou et al., 2013; Houbracken et al. 2011). This thesis examined the
requirement of ATF3 for changes in the expression of transcription factors involved in
ADM. While no histological differences were observed in Atf3-/- mice immediately after
cessation of injury; IF analysis supported a model in which ATF3 is required for
repressing MIST1 expression during RP injury. The exact mechanism by which ATF3
represses MIST1 during RP injury was not examined directly, our laboratory’s previous
work indicated the Mist1 gene is directly regulated by ATF3. Utilizing chromatin
immunoprecipitation followed by Next Generation Sequencing (ChIP-Seq) the study
showed ATF3 repressed Mist1 by recruiting inhibitory histone deacetylase 5 (HDAC5) to
the Mist1 promoter (Fazio et al., 2017). It is possible that as long as ATF3 expression is
maintained, HDAC5 remains bound to the MIST1 promoter, repressing its activity. In
addition, along with MIST1 repression, there is a potential that ATF3 represses other
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transcription factors involved in maintaining acinar cell identity, such as Nr5a2 and
Rbpjl. Further, it is also likely that after the immediate cessation of injury, the pool of
cells that lack ATF3 and maintain MIST1 expression have not fully differentiated into a
duct fate and have greater proliferative potential to cope for the loss of acinar cells. This
theory would support the Ki67 results that show high proliferative capacity in Atf3-/tissue compared to WT tissue immediately one-day after the cessation of injury.
Increased expression of both SOX9 and PDX1 are correlated with ADM (Stanger &
Hebrok, 2013; Pinho et al., 2011; Rooman & Real, 2012). In addition, SOX9 and PDX1
are required for the maintence of ADM morphology along with the regulation of duct
specific genes such as Ck19 (Carrière et al., 2011). My findings suggest that in the
absence of ATF3 both SOX9 and PDX1 expression are reduced compared to WT mice.
This was further supported by reduced CK19 accumulation (marker of duct cells) in
Atf3-/- tissue compared to WT tissue as seen by IHC analysis. Although, SOX9, PDX1
and CK19 expression is reduced in the absence of ATF3, there still appears to be ductlike structures that resemble ADM in the pancreas as seen by both H&E and IHC
analysis. It is possible that other ADM promoting factors are compensating for the
decreased expression of SOX9 (the main transcription factor involved in ADM
development) in the absence of ATF3. Studies show that injury alone can induce ADM
development to some extent in Sox9-deficient acinar cells, although Sox9 overexpression
is known to greatly promote ADM (Delous et al., 2012; Manfroid et al., 2012). It is also
possible that hepatocyte nuclear factor 6 (HNF6) compensates for the absence of SOX9
allowing ADM development, although, less efficiently (Prévot et al., 2012; Manfroid et
al., 2012). The expression of SOX9 and HNF6 work in synergy to promote ADM
development and the expression of Hnf6 is not maintained in more progressive lesions
(PanIN lesions) while SOX9 is maintained (Prévot et al., 2012; Manfroid et al., 2012).
Given the reduced accumulation of CK19, it does appear that ADM is significantly
impaired in the absence of ATF3. It is possible that putative ADM is not derived from
acinar cells (i.e. they are physiological ducts).
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4.2.3 Regulation of extrinsic signalling factors in RP
The molecular program of ADM is widely studied whether it be through intrinsic or
extrinsic signalling pathways (Bryant et al., 2014; O’Hagan & Heyer, 2011; Liu &
Kaufman, 2003; Ron & Walter, 2007). However, the mechanism by which ADM
programming is triggered as a result of pancreatic insult is still not well understood. One
postulated mechanism of ADM development by extrinsic signalling involves the release
of the cytokine TNF-α by macrophages, which can infiltrate the parenchymal tissue as
result of inflammation and damage (Clark et al., 2007). TNF-α can bind EGFR, stimulate
over-activation of MAPK signalling, and induce the formation of ADM both in culture
and mouse models (Liou et al., 2015; Liou et al., 2016). Although not examined in the
context of RP, ATF3 may play a role in macrophage infiltration and EGFR signalling
during RP. Our previous study examining acute pancreatitis showed genes linked to the
EGFR signalling pathway were indeed downregulated in the absence of ATF3. Hedgehog
signalling is another factor involved in promoting ADM development. Damaged acinar
cells through Hedgehog paracrine signalling activate fibroblast cells into stellate cells
(Yauch et al., 2008; Bailey et al., 2008). My results showed ATF3 does not affect overall
pancreatic fibrosis based on the amount of collagen deposits seen in the ECM post injury
and recovery. However, it is possible that ATF3 has a specific role in pancreatic stellate
cells. There are a number of studies that suggest ATF3 regulates fibrosis in other systems
(Mallano et al., 2016; Kim et al., 2017). In contrast, there remains a bigger role for ATF3
signalling in acinar cells compared to cells of the stroma. Indeed, a previous study in our
lab showed a 60-fold increase in ATF3 expression in acinar cells within four hours of
acute pancreatitis (Fazio et al. 2017). As a result, this thesis focused heavily on intrinsic
factors in acinar cells involved in triggering ADM.
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4.2.4 Role of ATF3 in the presence of oncogenic KRAS
Next, I wanted determined whether the loss of ATF3 would reduce or prevent ADM in
the presence of oncogenic KRAS. To do this, oncogenic KRAS was activated specifically
in adult acinar cells followed by the induction of acute pancreatic injury. Pancreatic
injury resulted in both Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ and Atf3-/-; Ptf1acreERT/+;
KrasLSL-G12D/+ mice losing body weight compared to Atf3+/+; Ptf1acreERT/+ and Atf3-/-;
Ptf1acreERT/+ mice within five weeks after injury. Surprisingly, Atf3-/-; Ptf1acreERT/+;
KrasLSL-G12D/+ mice lost significantly more body weight compared to Atf3+/+;
Ptf1acreERT/+; KrasLSL-G12D/+ mice, suggesting that overall health had been compromised.
Studies demonstrate KRASG12D activation along with pancreatitis is sufficient to induce
PDAC within five months (Guerra et al., 2007). Surprisingly, this thesis showed gross
morphological characteristics (based on nodules and fibrosis) of PDAC and confirmed
through histological grading that PDAC occurred in Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+
mice alone within two weeks of acute pancreatitis after oncogenic KRAS activation. It is
possible that PDAC incidences are occurring earlier as a result of widespread crerecombination, thus greater degree of KRASG12D activation seen in acinar cells (97.98 ±
0.17% Cre-efficiency).
Gross morphologically Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ pancreata appeared small in
size, which suggests that the loss in body weight is likely correlated to the loss of healthy
pancreatic tissue. It is unlikely that the size differences of the pancreas seen between
Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ and Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ mice is due to
differences in water weight alone (edema), as the tissue histologically showed no signs of
epithelial cell swelling in both Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ and Atf3-/-;
Ptf1acreERT/+; KrasLSL-G12D/+ mice. It is possible that there may be differences in stromal
fluid turgor pressure that could be resulting in the differences seen in tissue size.
Analyzing dry tissue weight would help address this question in the future. More likely,
the differences seen in pancreatic size may be explained by differences in lesion grade
and accumulation. To address this, tissue samples were analyzed and graded
histologically.
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Interestingly, my results based on H&E indicated no overt differences in lesion grade
between Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ and Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+
pancreatic tissue within two weeks of pancreatic injury. However, by five weeks of
injury, Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue showed lower incidences of high grade
PanIN3 lesions and no incidences of PDAC compared to Atf3+/+; Ptf1acreERT/+; KrasLSLG12D/+

tissue. In accordance with other studies (Chen et al., 2018; Bailey et al., 2014;

Rooman & Real, 2012) we showed through lineage tracing that PanIN lesions were
indeed arising from acinar cells in both Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ and Atf3-/-;
Ptf1acreERT/+; KrasLSL-G12D/+ tissue and not resident duct cells. Further, studies indicate that
mucins (MUC1 and MUC4 proteins primarily) are atypically expressed in PDAC and is
strongly correlated with tumour size, dysplasia and high grade PanIN lesions (Suh et al.,
2017). Similarly, my work showed a high degree of mucin accumulation in Atf3+/+;
Ptf1acreERT/+; KrasLSL-G12D/+ tissue within five weeks of injury based on Alcian blue
analysis that targets all acidic mucins. In contrast, Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+
tissue had lower levels of mucin compared to Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+ tissue.
These findings support histological findings that indicate a reduction in high-grade
lesions in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue. Although, similar incidences of high
grade PanIN lesions were seen early on in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue, it is
possible that further progression to PDAC does not occur in Atf3-/-; Ptf1acreERT/+; KrasLSLG12D/+

mice, or that there is an increase in apoptotic cell death that leads to loss of PanIN3

lesions within the span of five weeks after injury. This would potentially explain the
gross morphological size differences seen between the genotypes. In either event more
epithelial tissue is still lost in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ mice.
It is possible that the reduction in epithelial cells as marked by YFP and CK19 staining is
one factor that resulted in an atrophied pancreas seen in Atf3-/-; Ptf1acreERT/+; KrasLSLG12D/+

tissue. It is also possible that epithelial cells exhibit reduced proliferation, which is

supported by reduced Ki67+ cells in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue. To further
expand on these two key findings, it would be important to co-stain for CK19 and YFP to
determine if ducts derived from non-acinar cells within the pancreas expand upon
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pancreatic injury. My analysis identified large duct-like lesions that do not express YFP
in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue, which would support this theory. Finally, it
is possible that high-grade lesions within Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue cannot
be maintained and undergo apoptotic cell death by week five post injury. This would
support the low lesion accumulation seen at week five and the remaining non-acinar
lineage lesions seen in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue that are likely just duct
cells. In the future, makers of cell death need to be examined to factor in this possibility.

4.2.5 Regulation of factors by ATF3 in KRASG12D background
My findings demonstrate that along with reduced CK19 accumulation there is reduced
SOX9 and pERK accumulation in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+mice. The
downstream mediators of the MAPK signalling pathway are often targeted to attenuate
ADM and PanIN lesion progression in PDAC (Engelman et al., 2008; Castellano et al.,
2013). The exact point in which ATF3 regulates the MAPK signalling pathway is hard to
delineate. Currently, no antibody specific for oncogenic KRAS exists to show that
oncogenic KRAS activity is directly affected by ATF3 expression (Nussinov et al.,
2018). Although, potential mechanisms can be postulated for MAPK and SOX9
expression by ATF3 based on other studies. For example, in non-small-cell lung
carcinoma (NSCLC) ATF3 is known to regulate MEK and pERK to promote
carcinogenesis (Bar et al., 2011). It is possible that ATF3 similarly could be regulating
upstream mediators such as MEK and RAF along with pERK in PDAC. In future studies,
upstream mediators will be examined to address this question. Interestingly, a study done
by Chen et al., 2015 found that depletion of Nuclear Factor of Activated T cells c1
(NFATc1) caused a loss of SOX9 expression even upon EGFR activation. Further, the
study found that NFATc1 was recruited to the Sox9 promoter in response to EGFR
activation. It could be possible that ATF3 is upregulating pERK expression to induce
EGFR mediated NFATc1 activation along with directly binding the Sox9 promoter. The
exploration of NFATc1 expression in the context of ATF3 in a KRASG12D background
may provide us with a potential mechanistic axis for ADM regulation. In contrast, it is
also likely that ATF3 may be influencing its effects in a non-acinar cell manner to
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promote PDAC. To address this point, cells of the microenvironment were examined in
in the context of oncogenic KRAS.
Since this thesis utilized a global knockout for Atf3, we cannot discern acinar from nonacinar roles of ATF3. This is important since ATF3 affects cancer progression in other
systems (Gardian et al., 2012; Kurahara et al., 2011; Helm et al., 2014). The lack of Atf3
expression globally provides the comparative possibility of examining other cell types
that may be contributing to PDAC progression. My findings showed that there was more
fibrosis within two weeks of injury in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue and was
found to be comparable by five weeks of injury to Atf3+/+; Ptf1acreERT/+; KrasLSL-G12D/+
tissue. Interestingly, α-SMA protein expression was found to not differ between the
genotypes at both time points. It is unlikely that stellate cells as marked by α-SMA alone
is capable of remodelling the ECM. Rather, it is likely a complex interaction between
macrophages and stellate cells that results in significant degree of fibrosis seen in PDAC
(Shi et al., 2014). Although, precise macrophage-stellate interactions were not studied,
my results showed less macrophage infiltration in Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+
tissue within five weeks of injury. Tumor-associated macrophages (TAMs) promote
cancer fibrosis by secreting factors that activate fibroblast-mediated extracellular matrix
remodeling (Clark et al., 2007). Interesting, it is possible that early into injury, TAMS
infiltrate the Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ ECM and promote fibrosis, but over time
undergo cellular death or infiltration is prevented in the absence of ATF3 later in
pancreatic injury. It is difficult to draw mechanistic conclusions without precisely
knocking out ATF3 in stellate cells and macrophages. Future studies will examine
ATF3’s role in a cell specific manner.
In summary, the findings in this study support a role for ATF3 in pancreatic injury. In the
context of RP, it was shown that the lack of ATF3 maintains factors involved in
promoting acinar cell maturation in addition to repressing factors involved in promoting
ADM. As a result, the lack of ATF3 promoted significant tissue regeneration. In the
context of oncogenic KRAS, the lack of ATF3 similarly repressed factors involved in
ADM and prevented further high grade PanIN3 lesion development. Interestingly, the
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pancreas atrophied in size likely due to the lack of lesion accumulation or potentially due
to cellular death in addition to less lesion accumulation. A proposed schematic model of
the findings can be seen in (Figure 4.1).

84

Figure 4.1. Purposed model for ATF3 in experimental RP and its role in the context
of oncogenic KRAS. In this model, the lack of ATF3 allows for increased tissue
regeneration in experimentally induced RP. Once oncogenic KRAS is activated the lack
of ATF3 reduces high grade PanIN3 lesions and has an affect on the fibroinflammatory
profile of the tissue within five weeks of post CIP.
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4.3 Limitations & Future directions
The limitations for this study in the context of RP as alluded before includes the lack of
immune profiling in addition to the lack of EGFR signalling pathway analysis. It would
have been interesting to determine if the lack of ATF3 altered macrophage infiltration
early into damage or during recovery. Secondly, the examination of the EGFR signalling
pathway would have highlighted potential mechanisms between the ATF3-pERK-SOX9
axis in promoting ADM development and progression. In the context of oncogenic
KRAS, this study would have benefited if cellular death was examined to rule out the
possibility of apoptotic cellular death accounting for the atrophied pancreatic size seen in
Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ pancreata.
In future studies, to further determine if ATF3 binding of promoters persists throughout
RP, it could be beneficial to run ChIP-seq for acinar cells isolated from each time point.
This would help answer if ATF3 is still bound and is altering transcription or if other
transcription factors takeover and ATF3 becomes dispensable. To tease out intracellular
mechanisms that promote ADM, the investigation of transcription factors involved in this
pathway could be examined ex-vivo in culture. This would better solidify current in-vivo
findings.
This study showed that oncogenic KRAS alone in the presence or absence of ATF3
promotes focal lesions within 5 weeks of injury. In future long-term studies, it would be
interesting to determine if Atf3-/-; Ptf1acreERT/+; KrasLSL-G12D/+ tissue with oncogenic
KRAS activation but without injury limits PanIN progression compared to Atf3+/+;
Ptf1acreERT/+; KrasLSL-G12D/+ mice alone. In addition, lower doses of tamoxifen may be
administered to induce focal recombination of oncogenic KRAS activation and determine
if lesions prevented from developing into high grade lesions when injury is induced in the
absence of ATF3. Also, it is difficult to delineate the cell-specific contributions of ATF3
due to Atf3 being globally knockout. To tease out a potential mechanism, Atf3 can be
ablated in a cell specific manner in future studies.
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APPENDICES
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Appendix 1. ADM and PanIN lesion grade classification based on cellular
morphology. Representative H&E images show ADM and varying stages of PanIN
lesions. Putative ADM was classified based on cuboidal cellular morphology (black
arrow points to ADM). PanIN1 lesions were classified based on columnar cellular
morphology (white arrow points to PanIN1 lesions). PanIN2 and PanIN3 lesions were
classified based on the loss of cellular polarity along with nuclear atypia. PDAC was
classified according to a subset of cancerous cells encapsulated by fibrosis and
inflammatory cells.
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